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CHAPTER I 
 
INTRODUCTION 
 
The human body is composed of 10 trillion cells, each of which contains 2 meters of 
DNA compacted into a nucleus that is ~10 µm in diameter. Added together, our bodies 
contain over 12 billion miles of DNA, which must be maintained and replicated faithfully 
to ensure necessary cellular functions and to prevent a variety of nefarious illnesses, 
including cancer. The unique complimentary nature of DNA provides a redundant code 
that allows the genome to be replicated and repaired in a manner that promotes genomic 
stability (1-3). However, due to the length, double helical structure, and packaging of the 
DNA molecule into chromosomes, the cell must overcome significant topological 
problems (including over and underwinding, knotting and tangling) that arise as a result 
of normal cellular processes such as replication, transcription and recombination (4-8). 
These topological problems are resolved by DNA topoisomerases. 
 
DNA Topology 
 Topological properties of DNA are those that cannot be altered without breaking 
one or both strands of the double helix (4). Because DNA is comprised of two 
interwound nucleic acid strands, and the genomes of all known organisms are very long 
or circular (or both), two distinct topological issues arise (4,6-8). Proliferating cells must 
be able to cope with both of these topological issues in order to survive. 
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 The first issue is related to the torsional stress on the double helix. DNA from all 
species of eubacteria and eukaryotes is globally underwound ~6% (4,9). DNA under 
torsional stress is termed supercoiled, because underwound (or overwound) molecules 
writhe about themselves to form superhelical twists (4,9,10). Underwound and 
overwound molecules are called negatively and positively supercoiled, respectively 
(Figure 1). Negative supercoiling puts energy into the genetic material and makes it 
easier to separate the two strands of the double helix for replication and transcription 
(4,9,10). Thus, DNA underwinding increases the rates of these two fundamental 
processes. In contrast, the movement of DNA tracking systems (such as replication forks 
and transcription complexes) through the double helix locally overwinds the DNA ahead 
of their actions. Since overwinding makes it harder to pull apart the double helix, it 
blocks many essential cellular processes (4,11,12) (Figure 2). 
 The second issue is related to the extreme length of genomic DNA. Nucleic acid 
knots (intramolecular) and tangles (intermolecular) are formed routinely during a variety 
of ongoing cellular processes including DNA recombination and replication (Figure 1). 
DNA knots impair the ability to separate the two strands of the double helix and reduce 
the tensile strength of the genetic material. DNA tangles must be resolved in order for 
daughter chromosomes to segregate properly during meiosis and mitosis (4,6-9,11). 
Consequently, these two topological structures can be lethal to cells if they are not 
resolved. 
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Figure 1. Topological relationships within DNA. DNA molecules are 
shown as circular ribbons for simplicity. Top: Relaxed DNA is not under 
torsional stress. DNA underwinding and overwinding results in negative [(–) 
SC] or positive supercoiling [(+) SC], respectively. The directionality of the 
DNA is shown by arrowheads. Supercoils are shown as writhes. By 
convention, each writhe is given an integral value of -1 or +1. Middle: 
Intramolecular knots and intermolecular tangles can also form in DNA. 
Bottom: Negative and positive supercoils are denoted as “right-handed” and 
“left-handed”, respectively. Adapted from (9). 
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Figure 2. Topological changes associated with nuclear processes. A, 
DNA ends are tethered to membranes or the chromosome scaffold 
(represented by green lines) and are unable to rotate. Therefore, separation 
of the double helix and movement of DNA tracking systems (such as 
replication machinery represented by purple rods) through the immobilized 
DNA segment induces acute overwinding (i.e, positive supercoiling) (B). C, 
Compensatory underwinding (negative supercoiling) behind the replication 
machinery allows some of the torsional stress in the pre-replicated DNA to 
be translated to the newly replicated daughter molecules. Adapted from (15). 
 
Replication A 
B 
C 
+SC 
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DNA Topoisomerases 
 In order to maintain the appropriate level of DNA supercoiling and remove knots 
and tangles from the genetic material, cells encode enzymes known as topoisomerases 
(5,6,13-15). Topoisomerases modulate these topological structures by creating transient 
breaks in the DNA backbone. There are two classes of topoisomerases that can be 
distinguished by the number of DNA strands that they cleave during their catalytic 
cycles. Type I topoisomerases alter DNA topology by creating a transient single-stranded 
break in the genetic material and facilitating controlled rotation of the double helix about 
(or passage of the opposite strand through) the nick (16-19). Type II topoisomerases act 
by generating a transient double-stranded break, through which they pass a separate intact 
double helix. To maintain genomic integrity during DNA cleavage, topoisomerases form 
covalent links between active site tyrosyl residues and the newly generated DNA termini. 
These covalent protein-cleaved DNA complexes, known as “cleavage complexes,” are 
hallmarks of all topoisomerases irrespective of enzyme classification (5,6,14,16-20). 
Because type I topoisomerases create single-stranded breaks in the genetic material, they 
can regulate levels of DNA supercoiling. However, because type II topoisomerases 
generate double-stranded breaks in the DNA backbone, they can resolve knots and 
tangles in addition to removing torsional stress from the genetic material (Figure 3). Both 
type I and type II topoisomerases perform critical cellular functions that allow the 
progression of virtually all events in the cell that involve the genetic material (13,15-
17,19). 
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Figure 3. Topological structures resolved by DNA topoisomerases.  
DNA supercoils that result from replication and transcription are relaxed by 
both topoisomerase I and topoisomerase II. Due to its double stranded 
cleavage/strand passage mechanism, type II topoisomerases resolve knots 
and tangles in the genetic material that result from recombination and repair 
processes. Type II topoisomerases also decatenate interlocked sister 
chromatids at mitosis. 
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Type I Topoisomerases 
 With one exception, type I topoisomerases are denoted by “odd” numerals. 
Historically, type I topoisomerases have been divided into two subfamilies: type IA and 
type IB (6,16,19,21,22). There are several key differences between the two subfamilies. 
First, type IA topoisomerases covalently attach to the 5’-terminus of DNA during the 
cleavage reaction and resolve topological issues via a single-strand passage mechanism 
(16,19,21-24). In contrast, type IB enzymes covalently attach to the 3’-terminus of the 
cleaved DNA strand and act via a controlled rotation mechanism (16-18,25,26). Second, 
type IA enzymes require single-stranded DNA as a substrate and thus are capable of 
relaxing only negatively supercoiled substrates (21,22,27). Type IB enzymes do not 
require single-stranded substrates and can relax both negatively and positively 
supercoiled molecules (16,17,25-27). Third, while neither subfamily (with the exception 
noted below) requires a high–energy cofactor for enzymatic activity, type IA members do 
require a divalent cation for catalysis, while type IB members do not. However, catalysis 
by type IB topoisomerases is stimulated by divalent cations (16,18). Fourth, to date there 
are no known drugs that target topoisomerases in the IA subfamily. In contrast, several 
classes of molecules that have chemotherapeutic potential target type IB topoisomerases, 
specifically the eukaryotic enzymes (18,27,28). The clinical importance of these 
compounds and their actions against human topoisomerase I will be discussed later. 
 Prokaryotes encode several type I enzymes, including topoisomerase I and 
topoisomerase III, which belong to the type IA subfamily (16,21,22).  Additionally, many 
hyperthermophilic prokaryotes encode reverse gyrase. This enzyme, which introduces 
positive supercoils into the genomic material, is the only type I topoisomerase that 
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requires ATP for catalysis (16,19,21,22). Archaeoglobus fulgidus reverse gyrase (29,30) 
was used to generate the positively supercoiled substrates employed in this dissertation.  
 Humans encode four type I topoisomerases: nuclear topoisomerase I, mitochondrial 
topoisomerase I (mt topoisomerase I), and topoisomerase IIIα and IIIβ (Table I). Nuclear 
and mitochondrial topoisomerase I are type IB enzymes while both topoisomerase III 
isoforms belong to the type IA subfamily (6,15-17). Nuclear topoisomerase I and 
topoisomerase IIIα are required for proper development (31,32). Less is known about mt 
topoisomerase I and topoisomerase IIIβ, though mice that lack topoisomerase IIIβ display 
infertility, aneuploidy and reduced lifespan (33). Because the activity of human nuclear 
topoisomerase I is a focus of work presented in this dissertation, this enzyme will be 
discussed further below. 
 
Human Topoisomerase I Catalytic Cycle 
 Human topoisomerase I, a 91kD monomeric enzyme, carries out its catalytic 
function in five discrete steps (16-18) (Figure 4): 
 Step 1: Noncovalent binding of the enzyme to a DNA substrate.  Topoisomerase I 
binds preferentially at nodes of DNA crossovers and thus prefers supercoiled substrates 
of either handedness (34).  
 Step 2: Generation of a single stranded break in one strand of the double helix and 
covalent attachment of the enzyme to the 3’-terminus of the cleaved DNA strand, 
creating the “cleavage complex”. Human topoisomerase I shows some substrate 
preference for DNA surrounding the site of cleavage [5’–(A/T)(G/C)(A/T)T–3’] with the 
enzyme forming  a covalent attachment to the 3’ thymine (17). 
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 Step 3: Relief of torsional stress in the DNA by a ‘controlled rotation’ mechanism 
in which DNA relaxation proceeds by rotation of the free 5’ hydroxyl DNA end around 
the intact DNA strand. This relaxation is ‘controlled’ due to steric interactions by the 
surrounding topoisomerase I enzyme that restrict free movement (17,25,26).   
 Step 4: Religation of the cleaved DNA strand in a reaction that is the reverse of the 
cleavage reaction. This action regenerates an intact DNA substrate and the active site 
tyrosine of topoisomerase I. The catalytic mechanism of topoisomerase I allows it to 
relax DNA supercoils in steps of n, meaning that more than one supercoil can be relaxed 
before DNA religation takes place (16,17,25,26). 
 Step 5: Dissociation of the enzyme from the DNA substrate or initiation of a new 
round of catalysis. 
 
Human Topoisomerase I Domain Structure 
 Human topoisomerase I consists of four domains defined by crystal structure and 
limited proteolysis studies (16-19,21,35) (Figure 4). The N-terminal domain (amino acids 
1-214) is a poorly conserved region that contains multiple nuclear localization signals and 
interaction sites for several proteins including p53, nucleolin, and WRN helicase (36-38). 
This region of the protein is dispensable for activity in vitro. The core domain (amino 
acids 215-635) contains all of the residues needed for enzyme catalysis with the 
exception of the catalytic tyrosine. The core domain also provides structures for DNA 
substrate recognition and binding, and can be further divided into three subdomains (core 
subdomains I-III) based on structural studies. The linker domain (amino acids 636-712), 
which connects the core subdomain III to the C-terminal domain, is protease  
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Figure 4. Domain structure and enzyme mechanism of human 
topoisomerase I. A, Domain organization of human topoisomerase I: N-
terminal domain (purple), core domain (red), linker (green) and C-terminal 
domain (orange) are shown. The N-terminal domain contains nuclear 
localization sequences (NLS) and sites for protein interactions. The 
conserved core contains residues required for catalysis and substrate 
recognition. The C-terminal domain contains the active site tyrosine. B, 
Schematic of topoisomerase I mechanism [adapted from (26)].  The lobed 
structure formed by topoisomerase I is shown as semi-circles connected by a 
putative hinge. Negative [(–)SC] and positive [(+)SC] supercoils are relaxed 
by controlled rotation in a clockwise or counter-clockwise direction, 
respectively.  
(–)SC 
Relaxation 
(+)SC 
Relaxation 
Open 
Cut Cut 
Bind 
B 
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sensitive and dispensable for catalytic activity.  The C-terminal domain (amino acids 
713-765) contains the catalytic tyrosine.  The core and C-terminal domain together are 
sufficient to reconstitute relaxation activity in vitro (16,17,19).  
 Structurally, topoisomerase I forms a bilobed clamp around the DNA duplex 
(16,17,19,21,26). The upper lobe, or cap, is made up of core subdomains I and II. The 
lower lobe is made up of core subdomain III and the C-terminal domain. A putative hinge 
region is located at the top of core subdomain III and is thought to control the opening 
and closing of topoisomerase I around DNA. Parts of the N-terminal domain are 
hypothesized to interact with DNA and the putative hinge. Steric interactions between 
DNA and portions of topoisomerase I require the bound DNA substrate to rotate in 
different directions in order to relax negative or positive DNA supercoils (16,17,25,26). 
The tight clamping of the two lobes of topoisomerase I around the DNA duplex creates a 
central cavity at the base of which the catalytic tyrosine is embedded (17).  
 The active site of human topoisomerase I contains a pentad of catalytic amino acids, 
R488, K532, R590, H632, and Y723 (the catalytic tyrosine), that are highly conserved 
among members of the type IB subfamily.  The first four amino acid residues help 
position the scissile phosphate for nucleophilic attack by Y723, which generates the 
phosphodiester linkage between the enzyme and the 3’ phosphate of the DNA backbone 
(16,17,19). This covalent linkage preserves the integrity of the genetic material during 
enzyme catalysis. 
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Cellular Roles of Human Topoisomerase I 
 
 Human topoisomerase I is constitutively expressed throughout the cell cycle. 
Topoisomerase I is thought to play a key role in relaxing the positive supercoils that are 
generated ahead of replication and transcription machinery so that these processes can be 
carried to completion (11,15-17). To this point, topoisomerase I is enriched in the 
nucleolus, where 40-60% of cellular transcription occurs on rDNA (17). Apart from its 
cleavage-ligation topoisomerase function, the enzyme also is implicated in transcriptional 
co-activation, seemingly facilitating the formation of the transcription activation complex 
TFIID–TFIIA on promoters (39). In addition to regulating topological issues associated 
with replication and transcription processes, topoisomerase I also may play roles in 
chromosome condensation (40), chromatin remodeling (41), DNA repair (37,38), and 
RNA splicing (42,43).  
 
Type II Topoisomerases 
 Type II topoisomerases are essential to all prokaryotic and eukaryotic organisms. 
They are highly conserved among species, and the eukaryotic enzymes appear to be 
direct descendents of ancestral bacterial proteins (6,14,16,19,22,24). There are two 
classes of type II topoisomerases, type IIA and type IIB, which are defined on the basis of 
homology. With one exception, type II topoisomerases are denoted by “even” numerals. 
Bacteria encode two type IIA enzymes, DNA gyrase and topoisomerase IV 
(6,14,16,19,22,24). Eukaryotes, in contrast, encode only one type IIA enzyme, 
topoisomerase II (44,45). It should be noted, however, that vertebrate species express two 
closely related isoforms of the enzyme, topoisomerase IIα and topoisomerase IIβ (13-
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16,46,47). Archaea and plants express the only known type IIB topoisomerase, 
topoisomerase VI. More in depth studies of the type IIB topoisomerase can be found in 
recent reviews (16,24,48). Because type IIA topoisomerases are considered in work in 
this dissertation, these enzymes will be discussed further below.     
  
Topoisomerase II Enzyme Mechanism 
 Type II topoisomerases interconvert different topological forms of DNA by the 
double-stranded DNA passage reaction depicted in Figure 5, which uses eukaryotic 
topoisomerase II as a representative enzyme. Note that the eukaryotic enzyme functions 
as a homodimer while the prokaryotic enzymes work as heterotetramers. Type II 
topoisomerases carry out their catalytic function in six discrete steps (5,6,14-16,19,20):  
 Step 1: Binding of the enzyme to two DNA segments, the gate segment and the 
transfer segment. Type II topoisomerases bind preferentially to DNA crossovers (34). 
 Step 2: Creation of a double-stranded break in the gate segment of DNA, 
generating the cleavage complex. The scissile bonds on the two strands of the double 
helix cut by topoisomerase II are staggered, and the enzyme generates cleaved DNA 
molecules that contain 4-base single-stranded cohesive ends at their 5’-termini (20,49-
51).  
 Step 3: Translocation of the transfer segment of DNA through the cleaved gate 
double helix. 
 Step 4: Rejoining (i.e., religation) of the cleaved DNA, establishing a post-strand 
passage cleavage/religation equilibrium. 
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 Step 5: Release of the translocated DNA helix through the opening of the C-
terminal gate of the type II enzyme. 
 Step 6: Closing of the protein gate, returning the enzyme to its original 
conformation. The type II enzyme can now either dissociate or start a new round of 
catalysis.  
 Type II enzymes require two cofactors in order to carry out their catalytic double-
stranded DNA passage reactions. First, they need a divalent cation for all steps beyond 
enzyme-DNA binding (52-55). While magnesium(II) appears to be the divalent cation 
that the enzymes use in vivo, other divalent metal ions such as calcium and manganese 
are sufficient for enzyme cleavage in vitro (52-54). Second, they use the energy of 
adenosine triphosphate (ATP) to drive the overall DNA strand passage reaction (56-60). 
Type IIA topoisomerases do not require ATP for DNA cleavage or ligation. However, the 
binding of this nucleoside triphosphate triggers DNA translocation (Figure 5, step 3), and 
its hydrolysis to adenosine diphosphate (ADP) and inorganic phosphate (Pi) is necessary 
for enzyme recycling (Figure 5, step 5). Normally, type II enzymes bind two molecules 
of ATP. Although hydrolysis of the cofactor is not a prerequisite for the strand passage 
event, it appears that this step proceeds more rapidly if it is preceded by hydrolysis of one 
of the bound ATP molecules (56-60).  
 
Topoisomerase II Domain Structures 
 Type II topoisomerases share a number of common structural motifs that are shown 
in Figure 6. The founding type II enzyme, bacterial DNA gyrase, is comprised of two 
distinct subunits, GyrA and GyrB (molecular mass ≈ 96 kDa and 88 kDa, respectively), 
 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The double-stranded DNA passage reaction of topoisomerase 
II can be separated into six discrete steps. 1) DNA binding to regions of 
helix-helix juxtaposition. 2) Double-stranded DNA cleavage (i.e., formation 
of the cleavage complex), which requires the presence of Mg2+ 
(physiologically) or other divalent metal ions. 3) Double-stranded DNA 
passage through the DNA gate generated by cleavage. This reaction requires 
the binding of 2 ATP molecules, and strand passage proceeds more rapidly if 
one of the two ATP molecules is hydrolyzed. 4) Ligation of the cleaved 
DNA. 5) Hydrolysis of the second ATP molecule, which allows release of 
the DNA through a C-terminal gate in the protein and promotes 6) enzyme 
turnover, which allows the enzyme to initiate a new round of catalysis. The 
protein (shown in blue) is based on crystallographic studies of yeast 
topoisomerase II. Modeled DNA helices are shown in green (horizontal) and 
yellow (coming out of the plane of the paper).  Adapted from (20). 
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and acts as an A2B2 tetramer (14,16,19,61-63). GyrA contains the active site tyrosyl 
residue that forms the covalent bond with DNA during scission, and GyrB contains 
consensus sequences for ATP binding. Bacterial topoisomerase IV is also an A2B2 
tetramer comprised of two subunits. In Gram-negative species, these subunits were first 
identified as proteins required for chromosomal partitioning, and are designated ParC 
(molecular mass ≈ 88 kDa) and ParE (molecular mass ≈ 70 kDa), which are homologous 
to the A and B subunits of DNA gyrase. In Gram-positive species, the subunits of 
topoisomerase IV are designated as the gyrase-like proteins GrlA and GrlB, respectively 
(14,16,19,61-63).  
 Eukaryotic type IIA topoisomerases are homologous to the bacterial enzymes 
(6,14,16,19,22,24). However, the two subunits have fused into a single polypeptide with 
protomer molecular masses ranging from ~160-180 kDa (depending on the species) 
(Figure 6). On the basis of amino acid sequence comparisons with bacterial gyrase, each 
topoisomerase II protomer can be divided into three distinct domains (6,14,16,19). The 
N-terminal domain of the enzyme is homologous to the B subunit of DNA gyrase (GyrB) 
and contains the binding site for ATP. The central domain is homologous to the A 
subunit of DNA gyrase (GyrA) and contains the active site tyrosyl residue. The C-
terminal domain of the eukaryotic enzyme contains nuclear localization sequences as well 
as amino acid residues that are phosphorylated in vivo (64-70). As will be discussed in 
Chapter III, the C-terminal domains of both the prokaryotic and eukaryotic type II 
enzymes also are important for enzyme recognition of DNA topology. However, because 
work in this dissertation focuses on human topoisomerases (Table I), only the eukaryotic 
type II enzyme will be discussed in more detail below.  
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Figure 6. Domain structures of type II topoisomerases. The domain 
structures of four type IIA topoisomerases, bacterial (Escherichia coli) DNA 
gyrase and topoisomerase IV, and human topoisomerase IIα and IIβ are 
shown. Regions of homology among the enzymes are indicated by colors. 
The N-terminal (i.e., GyrB) homology domains (purple) contain the regions 
responsible for ATP binding and hydrolysis. The vertical white stripes 
represent the three conserved motifs of the “Bergerat fold” that define the 
ATP-binding domain. The central (i.e., GyrA) homology domains (red) 
contain the active site tyrosyl residue that forms the covalent bond with 
DNA during scission. For human topoisomerase IIα and IIβ the variable C-
terminal domain (green) contains nuclear localization sequences (NLS) and 
phosphorylation sites (PO4).  
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Eukaryotic Type II Topoisomerases 
 
 The eukaryotic type II enzyme, topoisomerase II, was discovered in 1980 (71). 
Eukaryotic species such as yeast and Drosophila encode only a single type II 
topoisomerase (i.e., topoisomerase II) (44,45,72-74). However, as discussed above, 
vertebrates contain two isoforms, topoisomerase IIα and topoisomerase IIβ. These two 
isoforms share extensive amino acid sequence identity (~70%) but are encoded by 
separate genes (located at chromosomal bands 17q21-22 and 3p24 in humans, 
respectively). Topoisomerase IIα and topoisomerase IIβ also can be distinguished by 
their protomer molecular masses (~170 kDa and ~180 kDa, respectively) (14,75-78). 
 
Cellular Roles of Eukaryotic Topoisomerase II 
 Topoisomerase II plays a number of essential roles in eukaryotic cells and 
participates in virtually every major process that involves the genetic material (13-
16,19,20). The enzyme unlinks daughter chromosomes that are tangled following 
replication and resolves DNA knots that are formed during recombination (Figure 3). It 
also helps to remove the positive DNA supercoils that are generated ahead of replication 
forks and transcription complexes (20,79,80). Topoisomerase II is required for proper 
chromosome condensation, cohesion, and segregation, and appears to play roles in 
centromere function and chromatin remodeling. Finally, topoisomerase II is important for 
the maintenance of proper chromosome organization and structure, and is the major non-
histone protein of the mitotic chromosome scaffold and the interphase nuclear matrix 
(14,15,81-83). 
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 It is not obvious why vertebrate species encode two distinct topoisomerase II 
isoforms. Enzymological differences between topoisomerase IIα and topoisomerase IIβ 
are subtle, and relationships between these isoforms are not well defined. The only major 
enzymological characteristic that distinguishes topoisomerase IIα and topoisomerase IIβ 
is the fact that the α isoform removes positive DNA supercoils ~10–fold faster than it 
does negative, while the β isoform removes both at similar rates (79). The structural 
features of topoisomerase IIα that promote this enzymological difference will be 
discussed in Chapter III.  
 Topoisomerase IIα and topoisomerase IIβ have distinct patterns of expression and 
separate cellular functions. Topoisomerase IIα is essential for the survival of proliferating 
cells and is regulated over both cell and growth cycles (84-87). Enzyme levels increase 
throughout S-phase of the cell cycle and peak at the G2/M boundary (86,88,89). 
Topoisomerase IIα is found almost exclusively in proliferating tissues, is associated with 
replication forks, and remains tightly bound to chromosomes during mitosis (13,87,90-
92). Thus, it is believed to be the isoform that functions in growth-related processes, such 
as DNA replication and chromosome segregation.  
 Topoisomerase IIβ is dispensable at the cellular level but is required for proper 
neural development in mice (46,93,94). In contrast to the α isoform, the concentration of 
topoisomerase IIβ is independent of the cell cycle, and this isoform is found in most cell 
types regardless of proliferation status. Topoisomerase IIβ dissociates from chromosomes 
during mitosis and cannot compensate for the loss of topoisomerase IIα in mammalian 
cells (46,92,93). Although the physiological functions of the β isoform have yet to be 
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fully defined, recent evidence indicates involvement in the transcription of hormonally- 
or developmentally-regulated genes (95,96).  
 
Topoisomerases as Cellular Toxins 
 The concentrations of topoisomerase-DNA cleavage complexes are tightly 
regulated in cells (Figure 7).  These complexes normally have a short lifespan and are 
readily reversible. While topoisomerase activity is necessary for cellular survival, too few 
or too many topoisomerase cleavage complexes can have a detrimental effect on the cell. 
If concentrations of topoisomerase II-DNA cleavage complexes drop below threshold 
amounts, topological problems that arise during replicative processes are not resolved, 
and daughter chromosomes remain entangled, resulting in catastrophic mitotic failure. If 
concentrations of topoisomerase I- or topoisomerase II-DNA cleavage complexes are too 
high, several negative outcomes are possible, including mutagenic translocations or cell 
death due to genome fragmenting (13-15,20,27,80,97-100).  
 In addition to their varied and critical physiological functions, topoisomerases are 
targets for some of the most active antibacterial (targeting bacterial type II 
topoisomerases) and anticancer drugs (targeting human topoisomerase I and both 
isoforms of human topoisomerase II) in clinical use. These agents do not act by robbing 
cells of essential topoisomerase activity. Rather, drugs that target topoisomerases kill 
cells by dramatically increasing the concentration of covalent enzyme-DNA cleavage 
complexes (20,27,28,80,101-104).  
 The potential lethality of cleavage complexes rises substantially when DNA 
tracking enzymes such as polymerases or helicases attempt to traverse the covalently
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Figure 7. Effects of topoisomerase-cleavage complexes in the cell. 
Topoisomerase I and II cleavage complexes are transient in nature, and their 
cellular concentration is tightly regulated. If levels of topoisomerase II 
cleavage complexes fall too low, cells are unable to undergo chromosome 
segregation, resulting in slow growth rates and  mitotic failure. If levels of 
either topoisomerase I or topoisomerase II cleavage complexes are too high, 
they can be converted to permanent strand breaks which can lead to 
chromosome breakage and translocations. Both of these pathways can 
culminate in cell death. In a small percentage of patients treated with 
topoisomerase II poisons, DNA translocations at the MLL and PML-RARA 
chromosomal loci result in therapy-related leukemias. Adapted from (20). 
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bound topoisomerase “roadblock” in the genetic material. Such an action disrupts 
cleavage complexes and converts transient enzyme-mediated DNA breaks to permanent 
DNA breaks (20,80,98,99). These permanent breaks in the genome trigger the generation 
of chromosomal insertions, deletions, translocations, and other aberrations, and when 
present in sufficient numbers, initiate a series of events that culminates in cell death 
(20,80,98-100,105-107). Because the drugs that target topoisomerases convert these 
essential enzymes to potent cellular toxins that fragment the genome, they are referred to 
as topoisomerase “poisons” to distinguish them from drugs that act as catalytic inhibitors.  
 
Human Topoisomerase I in Chemotherapy 
 Human topoisomerase I is the target of an emerging class of drugs based on the 
parent compound camptothecin (27,28,108) (Figure 8).  Camptothecin was first 
discovered in 1966 during a screening for natural products with anticancer activity and 
was originally isolated from the bark of the Chinese Yew tree Camptotheca acuminata 
(109). Camptothecin acts by inhibiting the DNA religation reaction of topoisomerase I, 
trapping covalent topoisomerase I-nicked DNA complexes on the genetic material. Two 
derivatives of camptothecin, topotecan (a water soluble formulation) and irinotecan (a 
prodrug that is activated in vivo) are approved worldwide for the treatment of colorectal, 
gynecological, and other cancers. A third derivative, belotecan is approved for use in 
South Korea. These topoisomerase I-targeted anti-cancer agents are of special importance 
because they are active against a spectrum of cancers that have few other treatment 
options (27,28,108).  
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Figure 8. Topoisomerase I-targeted anticancer drugs. Camptothecin is a 
naturally occurring compound originally isolated from the bark of 
Camptotheca acuminata. Topotecan and Irinotecan are clinically prescribed 
derivatives that are used to treat a wide spectrum of cancers that have few 
other treatment options.  
 
 
Camptothecin 
Topotecan 
Irinotecan 
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 Several lines of evidence demonstrate that the anticancer properties of camptothecin 
result from its actions on topoisomerase I. First, yeast that lack topoisomerase I are 
immune to the effects of camptothecin (110,111).  Second, experiments to select for 
camptothecin resistance yield specific causal point mutation in topoisomerase I (112). 
Third, plants that produce camptothecin contain point mutations in their topoisomerase I 
enzymes that render them resistant to the effects of the drug (27,112,113). 
 Though effective, these camptothecin-based drugs are not without limitations.  At 
physiological pH, the opening of the lactone E-ring of the compound readily inactivates 
camptothecin (27,28,112). Additionally, camptothecin binds serum albumin and is thus 
less accessible for cellular uptake (114).  Topotecan and irinotecan are more stable than 
camptothecin and display reduced albumin binding. Other mechanisms that contribute to 
camptothecin resistance include cellular exclusion by drug efflux pumps, reduced 
topoisomerase I protein levels, and topoisomerase I mutations that decrease the 
sensitivity of the enzyme for these compounds (27,104,115-119). Thus, the development 
of new drugs that target topoisomerase I is of great clinical interest, and several new 
families of compounds that poison topoisomerase I currently are under investigation 
(27,28,118,120,121). The effects of DNA topology on the actions of anti-cancer drugs 
that affect topoisomerase I and implications for new classes of drugs that target the 
enzyme will be discussed in Chapter IV. 
 
Human Topoisomerase II in Chemotherapy 
 At the present time, six topoisomerase II-targeted anticancer agents are approved 
for use in the United States (Figure 9). Additional drugs that target the type II enzyme are 
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used worldwide. Drugs such as etoposide and doxorubicin (and their derivatives) are 
front-line therapy for breast and lung cancers, as well as a variety of leukemias, 
lymphomas, and germ-line malignancies (20,80,122-125).  Mitoxantrone is used to treat 
breast cancer as well as remitting cases of multiple sclerosis, an autoimmune disease 
(126,127). Both mitoxantrone and amsacrine are used to treat relapsed acute myeloid 
leukemia (128). Approximately one-half of all cancer chemotherapy regimens contain 
drugs targeted to topoisomerase II. Moreover, every form of cancer that can be cured by 
systemic chemotherapy is treated with these agents (97,122,125,128). 
 The topoisomerase II-targeted anti-cancer agents currently in clinical use act by 
interfering with the ability of the enzyme to religate the cleaved DNA strands 
(80,97,125).  Doxorubicin, mitoxantrone, and amsacrine have additional effects due to 
their ability to intercalate into the double helix (80,129-132). The affects that intercalative 
compounds have on the activity DNA topoisomerases will be explored in Chapter IV. 
 Topoisomerases were first suggested to be the target for certain anticancer drugs in 
the late 1970s when the laboratory of Dr. Kurt Kohn observed that protein-associated 
DNA breaks formed in cells treated with intercalative compounds (133,134). In the early 
1980s, the laboratory of Dr. Leroy Liu demonstrated that etoposide and related 
compounds specifically increased levels of DNA cleavage mediated by mammalian 
topoisomerase II in vitro and in vivo (129,135,136). In the late 1980s, the laboratory of 
Dr. Neil Osheroff showed that these compounds interfered specifically with the cleavage-
ligation reaction of the type II enzyme (137). Clinical development of new compounds 
that target the human enzyme is still robust today. 
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Figure 9. Topoisomerase II-targeted anticancer drugs. Clinically 
approved topoisomerase II-targeted agents are shown. These compounds are 
termed poisons because they act by increasing cellular levels of covalent 
topoisomerase II-DNA cleavage complexes. 
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Due to the high concentration of topoisomerase IIα in rapidly proliferating cells, 
this isoform probably is the more important target of anticancer therapy. However, 
circumstantial evidence suggests that the β isoform also contributes to drug efficacy 
(20,80,97).  Treatment of patients with drugs that target topoisomerase II, while 
potentially curative, comes with a cost.  Topoisomerase II poisons can cause numerous 
side effects, including myelosuppression and gastrointestinal and cardiac toxicities. 
Additionally, ~2-3% of patients treated with topoisomerase II-targeted agents develop 
specific treatment-related acute myeloid leukemias (AML) that include chromosomal 
translocations in the MLL (mixed lineage leukemia) breakpoint region at chromosomal 
band 11q23 (107,138,139). Occurrences of acute promyelocytic leukemias with t(15;17) 
chromosomal translocations after treatment with topoisomerase II poisons also have been 
reported (140,141). 
 Several studies suggest that topoisomerase IIβ may play a more important role than 
topoisomerase IIα in mediating off-target toxicities and generating leukemic 
chromosomal translocations (142-144). Currently, there is no method available for 
specifically targeting topoisomerase II poisons to cancer cells. To this point, interactions 
of etoposide-based compounds with DNA and topoisomerase II, and implications for 
more selective means of targeting these compounds to cancer cells will be discussed in 
Chapter V. 
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Scope of the Dissertation 
 Topoisomerases play critical roles in regulating the topological state of the genetic 
material. Topoisomerase I has long been assumed to act ahead of replication forks to 
relieve the positive torsional stress that accumulates during this process. Recent studies 
provide evidence that topoisomerase IIα preferentially relaxes positively supercoiled 
DNA and also may be acting to relieve positive superhelical stress associated with 
replication (15,16,80). However, very few studies have examined these enzymes on their 
purported cellular substrates. In addition to their cellular functions, topoisomerases are 
the targets for some of the most widely prescribed anticancer drugs currently in clinical 
use (20,27,28,97). These drugs act by stabilizing covalent topoisomerase-DNA cleavage 
complexes. It is the accumulation of these cleavage complexes ahead of DNA tracking 
systems that ultimately leads to cell death (20,27,80). Therefore, the goal of this 
dissertation is to more fully characterize the effects that DNA interactions have on the 
activities of topoisomerase I and topoisomerase II and drugs that target these enzymes.  
 Chapter I of this dissertation reviews DNA topology and type I and type II 
topoisomerases. Additionally, Chapter I discusses the role of human topoisomerase I and 
topoisomerase II as cellular toxins and chemotherapeutic targets. Chapter II describes the 
materials and methods utilized in the work presented in Chapters III-V.   
 Chapter III of this dissertation describes the structural features of human 
topoisomerases that are required for the recognition of DNA topology. Previous studies 
have shown that topoisomerase IIα, but not topoisomerase IIβ preferentially relaxes 
positively supercoiled DNA (79). Recent work shows that the C-terminal domain of the 
enzyme is required for this activity. Therefore, studies were undertaken to determine 
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which portions of the C-terminal domain are required for the recognition of DNA 
supercoil handedness for relaxation. My contributions to this project, which are presented 
in Chapter III, demonstrate that almost the entire C-terminal domain of topoisomerase IIα 
is required for the preferential relaxation of positive supercoils. Furthermore, removal of 
even the endmost 30 amino acids abolished this ability. These results have been 
published (145).  
 If topoisomerase I is acting ahead of replication forks, its preferred substrate should 
be positively supercoiled DNA.  Therefore, the relaxation and cleavage activity of human 
topoisomerase I were characterized on positively supercoiled substrates. Results 
presented in Chapter III show that topoisomerase I preferentially relaxes and cleaves 
positively supercoiled substrates.  It is notable that the work on DNA relaxation was a 
collaborative project and that only my contributions are shown here.  A more in-depth 
characterization of this property of topoisomerase I has been published in Frohlich et al. 
(146). I spearheaded the characterization of topoisomerase I cleavage on positively 
supercoiled DNA, and these results have been published in Gentry et al. (147). 
 Chapter IV of this dissertation examines the effects that DNA supercoil geometry 
has on topoisomerase-targeted anticancer agents. Results show that topoisomerase I 
maintains higher concentrations of cleavage complexes on overwound substrates in the 
presence of both camptothecin-based and non-camptothecin based anti-cancer drugs. This 
is thought to be due to increased baseline levels of cleavage on positively supercoiled 
substrates rather than an altered drug interaction in the enzyme-DNA complex. 
Additionally, intercalative compounds that are not traditional topoisomerase I poisons 
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enhance the ability of the enzyme to cleave negatively supercoiled substrates in vitro and 
in a human cancer cell line. These results have been published in Gentry et al. (147). 
 Results presented in Chapters III and IV show that the interaction of drugs with 
DNA can have a profound effect on the activity of both topoisomerase I and 
topoisomerase II. Chapter V of this dissertation examines the activity of F14512, a novel 
etoposide derivative with strong DNA interactions, against type II topoisomerases. 
F14512 contains a spermine moiety in place of the C4 gycosidic group of etoposide 
(148,149). This compound was developed to increase drug uptake via the polyamine 
transport system. However, the addition of the spermine moiety to the etoposide core 
resulted in a compound that is a DNA binder (148). Results show that F14512 is a potent 
poison of topoisomerase IIα and topoisomerase IIβ but does not change the fundamental 
mechanism of etoposide action (i.e., inhibition of DNA ligation). Rather, the linkage 
between the spermine and the drug core appears to enhance the stability of etoposide in 
the ternary enzyme-drug-DNA complex. Results from this work currently are under 
review in Gentry et al. Chapter VI contains conclusions that can be drawn from my work 
on topoisomerases. 
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CHAPTER II 
 
METHODS 
 
Materials 
Human topoisomerase IIα and topoisomerase IIβ were expressed in 
Saccharomyces cerevisiae and purified as described previously (150). A set of mutant 
human topoisomerase IIα enzymes that were partially deleted in their CTD or that 
replaced amino acids starting with residue 1501 with the corresponding portion of human 
topoisomerase IIβ were constructed, expressed in S. cerevisiae JEL-1Δtop1 under the 
control of the yeast Gal promoter, and purified as described previously (151). Human 
topoisomerase I was expressed in S. cerevisiae top1 null strain RS190 (a gift from R. 
Sternglanz, State University of New York at Stony Brook) and purified as described 
previously (152). Archaeoglobus fulgidus reverse gyrase was expressed in Escherichia 
coli C41(DE3) and purified according to Rodriguez (29). Negatively supercoiled pBR322 
DNA was prepared from E. coli DH5α using a Plasmid Mega Kit (Qiagen) as described 
by the manufacturer. Restriction enzymes, klenow exo-, calf phosphatase, and T4 
polynucleotide kinase were from New England Biolabs. [α-32P]dATP (6000 Ci/mmol), 
[α-32P]TTP (3000 Ci/mmol) and [γ-32P]ATP (~5000Ci/mmol) were obtained from NEN. 
Camptothecin, ethidium bromide, 9-aminoacridine, etoposide, and ciprofloxacin were 
from Sigma. Topotecan was from Alexis Biochemicals. Amsacrine was a gift from Dr. 
David Graves (University of Alabama at Birmingham). NSC706744 and NSC725776 
were gifts from Dr. Yves Pommier (NCI). Tas-103 and TOP-53 were gifts from Taiho 
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Pharmaceuticals. F14512 (patent WO 2005/100363) was synthesized as described 
previously (148,149) and was a gift from Dr. Christian Bailly (Pierre Fabre). 4′-Demethyl 
epipodophyllotoxin (DEPT) was the gift of Dr. Norma Dunlap (Middle Tennessee State 
University). Camptothecin and topotecan were stored at -20 ºC as 10 mM stock solutions 
in 100% DMSO and water, respectively. Amsacrine, 9-aminoacridine, etoposide, TOP-53 
and F14512 were stored at 4 ºC as 20 mM stock solutions in 100% DMSO. TAS-103 and 
ethidium bromide were stored at 4 ºC as 10 mM and 2.5 mM stock solutions in water, 
respectively. Ciprofloxacin was stored at -20 °C as a 40 mM stock solution in 0.1N 
NaOH. All other chemicals were analytical reagent grade. 
 
Procedures 
 
Preparation of Positively Supercoiled DNA 
Positively supercoiled pBR322 DNA was prepared by incubating negatively 
supercoiled plasmids with Archaeoglobus fulgidus reverse gyrase using a protocol 
modified from McClendon et al. (79). Reaction mixtures contained 18 nM negatively 
supercoiled pBR322 DNA and 250 nM reverse gyrase in a total of 250 µL of 50 mM 
Tris-HCl, pH 8.0, 10 mM NaCl, 10 mM MgCl2, and 1 mM ATP. Reactions were 
incubated at 95 °C for 5 min, halted by the addition of 13 µL of 375 mM EDTA, and 
cooled on ice. Proteinase K was added (10 µl of 4 mg/ml), and the reactions were 
incubated at 45 °C for 30 min to digest the enzyme. Samples were extracted with phenol: 
chloroform: isoamyl alcohol (25:24:1), and positively supercoiled DNA was precipitated 
with cold ethanol. Plasmids were resuspended in 25 µL of 5 mM Tris-HCl, pH 7.4, 
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containing 500 µM EDTA. To remove residual ATP, reactions were further purified 
through Bio-Spin 6 nucleic acid purification columns (BioRad) according to the 
manufacturer’s protocol. To make certain that differences between negatively and 
positively supercoiled substrates were not influenced by the temperature or other 
conditions used in the preparation protocol, negatively supercoiled plasmids were treated 
in a parallel fashion, except that reverse gyrase was omitted from reaction mixtures. 
 The average number of superhelical twists present in DNA substrates and the 
resulting σ values were determined by electrophoretic band counting relative to relaxed 
molecules. Typical of plasmids isolated from E. coli, negatively supercoiled plasmids 
contained ~15–17 negative superhelical twists per molecule (σ ≈ –0.035 to –0.039). 
Positively supercoiled plasmids contained ~15–17 positive superhelical twists per 
molecule (σ ≈ +0.035 to +0.039). Thus, the supercoiled substrates employed in this body 
of work contained equivalent numbers of superhelical twists but were of opposite 
handedness. To ensure that equal amounts of plasmid were used in all experiments, the 
DNA concentration was assessed by spectrophotometric analysis and confirmed by 
ethidium bromide staining of linearized plasmid substrates. 
 
Plasmid DNA Relaxation 
 Topoisomerase I. Topoisomerase I plasmid DNA relaxation reactions were based on 
the protocol of Frohlich et al. (146). Reaction mixtures contained 3.75 nM topoisomerase 
I, and 5 nM negatively or positively supercoiled DNA in a total of 20 µL of 
topoisomerase I relaxation buffer (50 mM Tris–HCl, pH 7.5, 0.1 mM EDTA, 50 mM 
KCl, 10 mM MgCl2, and 0.5 mM DTT).  Mixtures were incubated at 37 ºC for 0-10 min 
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and stopped by the addition of 3 µL of 0.5% SDS and 77 mM EDTA. Samples were 
mixed with agarose gel loading buffer (60% sucrose in 10 mM Tris-HCl, pH 7.9) and 
subjected to electrophoresis in 1% agarose gels in 100 mM Tris-borate, pH 8.3 and 2 mM 
EDTA. Following electrophoresis, gels were stained for 30 min with 0.5 µg/mL ethidium 
bromide. DNA bands were visualized by UV light and were quantified using an Alpha 
Innotech digital imaging system (San Leandro, CA). DNA relaxation was monitored by 
measuring loss of the initial supercoiled substrate. 
 Topoisomerase II. Topoisomerase II DNA relaxation assays were based on the 
protocol of McClendon et al. (79).  Reaction mixtures contained 1-2 nM wild-type or 
mutant human topoisomerase IIα enzymes, 1 mM ATP, and 5 nM negatively or 
positively supercoiled pBR322 DNA in a total of 20 µL of topoisomerase II relaxation 
buffer (10 mM Tris-HCl, pH 7.9, 175 mM KCl, 5 mM MgCl2, 0.1 mM NaEDTA, and 
2.5% glycerol). Mixtures were incubated at 37 ºC for the time indicated and stopped by 
the addition of 3 µL of 0.5% SDS and 77 mM EDTA.  Samples were mixed with agarose 
gel loading buffer, and subjected to electrophoresis in 1 % agarose gels in 100 mM Tris-
borate, pH 8.3 and 2 mM EDTA.  Gels were stained for 30 min with 0.5 µg/mL ethidium 
bromide.  DNA bands were visualized and quantified as above.  DNA relaxation was 
monitored both by the formation of the fully relaxed product and by the loss of the initial 
supercoiled substrate. 
 
Plasmid DNA Cleavage 
 Topoisomerase I. Unless indicated otherwise, topoisomerase I DNA cleavage 
reactions were carried out by incubating 5 nM positively or negatively supercoiled 
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pBR322 plasmid DNA with 11 nM human topoisomerase I in 20 µL of topoisomerase I 
cleavage buffer (10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 1 mM EDTA, 5 mM MgCl2, 5 
mM CaCl2, 2.5% glycerol). Except where noted, reactions were incubated for 2 min at 37 
ºC, and enzyme-DNA cleavage complexes were trapped by the addition of 2 µL of 5% 
SDS followed by 1 µL of 375 mM EDTA, pH 8.0. Proteinase K (2 µL of a 0.8 mg/mL 
solution) was added, and protein samples were incubated for 30 min at 45 ºC to digest the 
enzyme. Samples were mixed with 2 µL of agarose gel loading buffer, heated for 5 min 
at 45 ºC, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate, pH 
8.3, and 2 mM EDTA containing 0.5 µg/mL ethidium bromide. DNA bands were 
visualized with ultraviolet light and quantified using an Alpha Innotech digital imaging 
system. DNA cleavage was monitored by the conversion of covalently closed circular 
supercoiled plasmid DNA to nicked molecules. 
 The effects of anticancer drugs on topoisomerase I-mediated cleavage of positively 
or negatively supercoiled plasmid DNA were assessed in the presence of 0–10 µM 
camptothecin, topotecan, NSC 706744 or NSC725776, or 0–100 µM rebeccamycin. The 
effects of intercalators were assessed in the presence of 0–20 µM ethidium bromide, 0–20 
µM TAS-103, 0–100 µM 9-aminoacridine, or 0–400 µM amsacrine.  
 Topoisomerase II. Topoisomerase II cleavage reactions were carried out using the 
procedure of Fortune and Osheroff (153). Topoisomerase II DNA cleavage assays 
contained 110 nM human topoisomerase IIα or 220 nM human topoisomerase IIβ and 10 
nM negatively or positively supercoiled pBR322 in a total of 20 µL of topoisomerase II 
cleavage buffer (10 mM Tris-HCl, pH 7.9, 5 mM MgCl2, 100 mM KCl, 0.1 mM EDTA, 
and 2.5% (v/v) glycerol). Reactions were incubated for 6 min at 37 ºC, and processed as 
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in the above section. DNA cleavage was monitored by the conversion of covalently 
closed circular supercoiled plasmid DNA to nicked or linear molecules. DNA cleavage 
reactions were performed in the absence of ATP so that the topological state of the DNA 
would not change during the course of the reaction. It should be noted that the nucleotide 
cofactor does not influence the mechanism of topoisomerase II-mediated DNA scission. 
 Topoisomerase II assays were carried out in the absence of compound or in the 
presence of 0-100 µM etoposide, DEPT, TOP-53, or F14512. Some reactions also 
contained 0-1000 µM ciprofloxacin or 0–500 µM spermine. 
 
Site-specific Cleavage of Circular DNA  
 Site-specific DNA cleavage reactions contained 7 nM negatively or positively 
supercoiled pBR322 DNA and 14 nM human topoisomerase I (in the absence or presence 
of 5 µM topotecan) in a total of 160 µL of topoisomerase I cleavage buffer. Samples 
were incubated for 2 min at 37 ºC, and enzyme-DNA cleavage complexes were trapped 
by the addition of 16 µL of 1% SDS followed by 8 µL 375 mM EDTA. Proteinase K (3 
µL of a 4 mg/mL solution) was added, and mixtures were incubated for 30 min at 45 ºC 
to digest the topoisomerase I. Reaction products were purified by passage through 
Qiaquick spin columns (Qiagen) as described by the manufacturer. Plasmids were 
linearized by treatment with EcoRI and labeled with Klenow (exo-) in the presence of [α-
32P]dATP and [α-32P]TTP. Samples were treated with HindIII, and the singly end-labeled 
4,330 bp DNA fragment was purified by passage through a CHROMA SPIN + TE-10 
column (Clontech). Reaction products were normalized for radioactivity. Equivalent 
counts were mixed with 5 µL of polyacrylamide gel loading buffer (80% formamide, 10 
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mM sodium hydroxide, 1 mM sodium EDTA, 0.1 % xylene cyanol, and 0.1% 
bromophenol blue), and subjected to electrophoresis in 6% polyacrylamide sequencing 
gels. Gels were dried in vacuo, and DNA cleavage products were visualized with a Bio-
Rad Molecular Imager FX. 
 
Site-specific Cleavage of Linear DNA  
 Topoisomerase I. To determine specific sites of topoisomerase I cleavage on a linear 
substrate, BR322 was linearized, labeled, and the 4,330 bp EcoRI-HindIII fragment was 
isolated as described in the preceding section. DNA cleavage reactions (20 µL) contained 
4.4 nM labeled linear pBR322 DNA and 20 nM human topoisomerase I, in the absence of 
compounds or in the presence of topoisomerase I-targeted anticancer drugs (10 µM 
camptothecin or topotecan) or DNA intercalators (20 µM ethidium bromide, 20 µM 
TAS-103, 100 µM 9-aminoacridine, or 200 µM amsacrine). Reactions were incubated for 
2 min at 37 ºC and enzyme-DNA cleavage complexes were trapped by the addition of 2 
µL of 5% SDS followed by 1 µL of 375 mM EDTA, pH 8.0. Proteinase K (2 µL of a 0.8 
mg/mL solution) was added, and protein samples were incubated for 30 min at 45 ºC to 
digest the topoisomerase I. Reaction products were ethanol precipitated and resuspended 
in 6 µL of polyacrylamide gel loading buffer. Samples were subjected to polyacrylamide 
gel electrophoresis and analyzed as described in the preceding section. 
 Topoisomerase II. Linear DNA cleavage sites utilized by topoisomerase II were 
mapped using a modification (154) of the procedure of O’Reilly and Kreuzer (155). The 
pBR322 DNA substrate was linearized by treatment with HindIII. Terminal 5’-phosphate 
was removed by treatment with calf intestinal alkaline phosphatase and replaced with 
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[32P]phosphate using T4 polynucleotide kinase and [γ-32P]ATP. The DNA was treated 
with EcoRI, and the 4332 bp singly end labeled fragment was purified from the small 
EcoRI-HindIII fragment by passage through a CHROMA SPIN+TE-100 column 
(Clontech). Reaction mixtures contained 0.7 nM labeled pBR322 DNA substrate and 110 
nM human topoisomerase IIα or topoisomerase IIβ in 20 µL of DNA cleavage buffer 
supplemented with 0.5 mM ATP in the absence or presence of 1–5 µM F14512, 5–10 µM 
TOP–53, or 5–10 µM etoposide. Reaction mixtures were incubated at 37 °C for 6 min 
and processed and imaged as in the proceeding section. 
 
Ligation of Cleaved DNA  
 Topoisomerase I. Topoisomerase I DNA cleavage-ligation equilibria were 
established for 2 min at 37 ºC in topoisomerase I cleavage buffer that contained 10 µM 
camptothecin or 5 µM topotecan, as described in the section on topoisomerase I-mediated 
cleavage of plasmid DNA. Ligation was initiated by the addition of NaCl to a final 
concentration of 300 mM and terminated from 5 to 45 s by the addition of 2 µL 5% SDS. 
Samples were processed and analyzed as described for plasmid DNA cleavage. The 
percent DNA cleavage at time 0 was set to 100%, and ligation was monitored by 
quantifying the loss of nicked DNA over time.  
 Topoisomerase II. DNA ligation mediated by topoisomerase IIα was monitored 
according to the procedure of Byl et al. (156). DNA cleavage-ligation equilibria were 
established for 6 min at 37 °C in the absence or presence of 10 µM F14512, 50 µM 
TOP53, or 50 µM etoposide. Ligation was initiated by shifting samples from 37 to 0 °C. 
Reactions were stopped at time points ranging from 0-30 s by the addition of 2 µL of 5% 
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SDS followed by 2 µL of 250 mM EDTA, pH 8.0. Samples were processed and analyzed 
as described under plasmid DNA cleavage. Linear DNA cleavage product at time zero 
was set to 100% and DNA ligation was monitored by the loss of linear DNA. 
 
DNA Intercalation 
 Intercalation reaction mixtures contained 20 nM topoisomerase I and 5 nM 
negatively supercoiled pBR322 DNA in a total of 20 µL of topoisomerase I relaxation 
buffer. These experiments also contained 0–10 µM ethidium bromide or TAS–103, 0–50 
µM 9-aminoacridine, 0-100 µM amsacrine, or 0-100 µM F14512. Reactions containing 
20 µM ethidium bromide or 100 µM etoposide were included as positive and negative 
controls, respectively. Mixtures were incubated at 37 °C for 10 min, extracted with a 
phenol/chloroform/isoamyl alcohol mixture (25:24:1), and added to 3 µL of 0.77% SDS 
and 77 mM EDTA (pH 8.0). Samples were mixed with 2 µL of agarose gel loading 
buffer, heated at 45 °C for 5 min, and subject to electrophoresis in a 1% agarose gel in 
100 mM Tris-borate (pH 8.3) and 2 mM EDTA. Gels were stained with 1 µg/mL 
ethidium bromide, and DNA bands were visualized as described for plasmid DNA 
relaxation. 
 The DNA intercalation assay is based on the fact that intercalative agents induce 
constrained negative supercoils and compensatory unconstrained positive superhelical 
twists in covalently closed circular DNA (157,158). Therefore, as the concentration of an 
intercalative compound increases, a plasmid that is negatively supercoiled or relaxed (i.e., 
contains no superhelical twists) appears to become positively supercoiled. Treatment of 
an intercalated plasmid with topoisomerase I or topoisomerase II removes the 
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unconstrained positive DNA superhelical twists. Subsequent extraction of the compound 
allows the local drug-induced unwinding to redistribute in a global manner and manifest 
itself as a net negative supercoiling of the plasmid. Thus, in the presence of an 
intercalative agent, topoisomerase treatment converts relaxed plasmids to negatively 
supercoiled molecules.  
 
Formation of Topoisomerase I-DNA Cleavage Complexes in Cultured Human Cells 
 Human CEM leukemia cells were cultured under 5% CO2 at 37 °C in RPMI 1640 
medium (Cellgro by Mediatech, Inc) containing 10% heat-inactivated fetal calf serum 
(Hyclone). The in vivo complex of enzyme (ICE) bioassay (as modified on the TopoGen, 
Inc., website) was utilized to determine levels of topoisomerase I-DNA cleavage 
complexes formed in the presence of anticancer drugs and/or intercalative compounds. 
Exponentially growing cultures were treated in absence of compound or presence of 10 
µM ethidium bromide, 5 µM topotecan, or 10 µM ethidium bromide + 5 µM topotecan 
for 1 h. Cells (~5 x 106) were harvested by centrifugation and lysed by the immediate 
addition of 3 mL of 1% sarkosyl. Following gentle homogenization in a Dounce 
homogenizer, cell lysates were layered onto a 2 mL cushion of CsCl (1.5 g/mL) and 
centrifuged at 45,000 rpm for 15 hr at 20 °C. DNA pellets were isolated, resuspended in 5 
mM Tris-HCl, pH 8.0, and 0.5 mM EDTA, normalized for the amount of DNA present, 
and blotted onto nitrocellulose membranes using a Schleicher and Schuell slot blot 
apparatus. Covalent complexes formed between human topoisomerase I and DNA were 
detected using a polyclonal antibody directed against human topoisomerase I (Topogen) 
at a 1:3000 dilution. 
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STD [1H] NMR Spectroscopy 
 NMR spectra were generated using conditions similar to those described previously 
(159,160). All NMR experiments were performed at 283 K using a Bruker Avance 700 
MHz spectrometer equipped with a 5 mm cryoprobe with z gradients. NMR buffers 
contained 10 mM sodium phosphate (pH 7.7), 250 mM KCl, 0.1 mM Na2EDTA, and 5 
mM MgCl2. Samples (400 µL) contained 5 µM human topoisomerase IIα and 500 µM 
F14512 and were maintained at 4 °C until data were collected. STD [1H]-NMR 
experiments employed a pulse scheme similar to that reported by Mayer and Meyer 
(161). A 2 s saturation pulse was used for the saturation, with on- and off-resonance 
irradiation frequencies of 0.5 and 17 ppm, respectively. The water signal was suppressed 
using excitation sculpting with gradients. For each experiment (on- and off-resonance 
irradiation), 256 scans were collected with a 2 s recycle time. Difference spectra were 
prepared by subtracting the on-resonance spectrum from the off-resonance spectrum. 
Signals resulting in the difference spectrum represent the nuclear Overhauser 
enhancement (NOE) difference signals generated by the transfer of irradiation energy 
from the enzyme to the bound ligand. Ligand protons in close spatial proximity with the 
enzyme displayed larger NOE signals. Mapping of the NOE signals with their proton 
assignments on the ligand revealed the ligand-binding epitope to human topoisomerase 
IIα. Spectra were processed using Bruker Topspin software. 
 
 Persistence of DNA Cleavage Complexes 
 The persistence of topoisomerase II-DNA cleavage complexes was determined using 
a modification of the procedure of Bandele et al. (162).  Initial reactions contained 50 nM 
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DNA, 550 nM topoisomerase IIα and 100 µM etoposide or 10 µM F14512 in a total of 
20 µL of topoisomerase II cleavage buffer. Reactions were incubate at 37 ºC for 6 
minutes then diluted 20 fold with 1x DNA cleavage buffer while remaining at 37 ºC. 20 
µL of reaction mix was removed and stopped with 2 µL 5% SDS at the indicated times. 
DNA cleavage at time 0 was set to 100 % and persistence of cleavage complexes 
determined as the decay of linear product over time. 
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CHAPTER III 
 
STRUCTURAL FEATURES OF TOPOISOMERASES REQUIRED FOR THE 
RECOGNITION OF DNA TOPOLOGY 
 
Introduction 
Historically, models have placed topoisomerase I ahead of nucleic acid tracking 
systems, acting to relieve positive torsional stress generated during replication and 
transcription. In contrast, models placed topoisomerase II behind the fork, acting to 
resolve DNA knots and tangles between newly replicated sister chromatids (11,14-17). 
Recently, however, studies have generated data that strongly suggests a role for human 
topoisomerase IIα ahead of replication forks (15,16,80). These studies also began to 
describe structural features of this enzyme that are important for its activity on positively 
supercoiled substrates. For example, it has been shown that topoisomerase II can 
compensate for the loss of topoisomerase I in S. cerevisiae, but the loss of both enzymes 
abruptly halts DNA synthesis (163,164). This finding indicates that the type II enzyme 
can assume the role of topoisomerase I, relaxing positive DNA supercoils ahead of the 
replication machinery. Additionally, topoisomerase IIα is associated with DNA 
replication forks in human cells (165). Finally, both isoforms of human topoisomerase II 
have been shown to recognize the geometry of DNA supercoils for cleavage (157). 
However, only topoisomerase IIα recognizes supercoil handedness during relaxation, 
removing positive supercoils >10 times faster than negative supercoils (79). A recent 
study has shown that the ability to preferentially relax positively supercoiled DNA is 
dependent on the C-terminal domain (CTD) of topoisomerase IIα. Results presented in 
this chapter indicate that almost the entire CTD is required for this preferential relaxation. 
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 It is likely that the topological state of DNA is regulated during the critical 
replication and transcription processes by both topoisomerase I and topoisomerase II.  
The relative contribution of the individual enzymes to these processes is an area of active 
investigation. However, in order to provide a complete picture of what is occurring in 
vivo, we must have an understanding of the catalytic activity of these enzymes.  
 If topoisomerase I is acting ahead of replication forks to relieve accumulating 
positive supercoils, then it stands to reason that this enzyme would recognize and 
preferentially act on a positively supercoiled substrate.  However, until recently, most 
studies have examined enzyme-mediated cleavage using negatively supercoiled DNA or 
linear substrates. Therefore, the ability of human topoisomerase I to relax and cleave 
positively supercoiled DNA was examined.  Results indicate that topoisomerase I is able 
to distinguish between the handedness of DNA supercoils during both catalytic processes. 
Furthermore, the enzyme is shown to both preferentially relax and cleave overwound as 
compared to underwound substrates. 
 
Results and Discussion 
 
Structural Features of Human Topoisomerase IIα Required for Topology Recognition 
Topoisomerase IIα and IIβ possess a high degree of amino acid sequence identity in 
their N-terminal ATPase and central DNA cleavage/ligation domains (~79% identity). 
However, the two enzymes diverge considerably in their CTDs (~31% identity) 
(14,16,45,166-168). To date, the only enzymological difference found between the two 
isoforms is the ability of topoisomerase IIα, but not topoisomerase IIβ, to preferentially 
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remove positive superhelical twists. Conversely, both enzymes maintain lower levels of 
DNA cleavage intermediates with positively supercoiled substrates (79,157). These 
findings suggest that type II topoisomerases discern DNA supercoil geometry in a 
bimodal fashion, using separate portions of the protein to distinguish nucleic acid 
handedness during different enzymatic processes. 
Because topoisomerase IIα and IIβ differ most significantly in their CTDs, it was 
proposed that this portion of topoisomerase IIα is responsible for the ability of the 
enzyme to preferentially relax positively supercoiled DNA. Indeed, removal of the CTD 
of the α isoform rendered the enzyme unable to preferentially relax positively 
supercoiled substrates. Furthermore, when the CTD of topoisomerase IIβ was replaced 
with that of the α isoform, the resulting enzyme preferentially relaxed positively 
supercoiled substrates. In contrast, a chimeric topoisomerase IIα that carried the CTD of 
the β isoform lost its ability to recognize the geometry of DNA supercoils during 
relaxation (145). These findings demonstrate that the ability to preferentially relax 
positive DNA supercoils resides in the CTD of topoisomerase IIα. Experiments presented 
below were undertaken to determine which portions of the CTD of human topoisomerase 
IIα confer this ability. 
 
Elements in the CTD of Human Topoisomerase IIα that Confer the Ability to Recognize 
Supercoil Geometry During DNA Relaxation  
There currently is no information available for the three-dimensional structure of the 
CTD of human topoisomerase IIα. However, crystal structures for the CTDs of the two 
bacterial type II enzymes, DNA gyrase (GyrA) and topoisomerase IV (ParC), have been 
solved (169-172). The CTD of GyrA adopts a unique fold, called a β-pinwheel, which 
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forms a closed circular structure made up of six “blades” (170,172). The outer rim of 
each blade contains a cluster of positively charged amino acids that are believed to 
interact with DNA (170,172). The CTD of ParC adopts a “broken β-propeller” structure 
that is similar to the β-pinwheel of GyrA, but lacks ring closure (169,171). Depending on 
the bacterial species, the CTD of ParC is predicted to contain as few as three and as many 
as eight blades. Once again, the outer rims of the blades contain positively charged amino 
acids. The CTDs of GyrA and ParC both have been shown to bind and bend DNA (170). 
 Extensive efforts were made by previous laboratory members to model the CTD of 
human topoisomerase IIα based on the structures of the bacterial type II enzymes. 
Unfortunately, homology between the CTDs of the different topoisomerase II species was 
too low to generate a predicted structure with confidence. However, amino acid sequence 
alignments comparing the CTDs of topoisomerase IIα with those of GyrA and ParC 
revealed similarities. Like the bacterial enzymes, human topoisomerase IIα contains a 
series of positively charged amino acid clusters that could potentially interact with DNA. 
Ten such clusters were identified and are indicated with red bars in Figure 10.  
 As a first attempt to narrow down the region(s) of the topoisomerase IIα CTD that is 
responsible for the preferential relaxation of positively supercoiled DNA, a series of 
nested C-terminally deleted enzymes was generated. This series contained full-length 
topoisomerase IIα, a mutant truncated human enzyme that included all of the predicted 
clusters of positive amino acids (truncated following amino acid 1521, hTop2αΔ1521), 
and enzymes that lacked one (hTop2αΔ1501), two  (hTop2αΔ1476), or six clusters  
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Figure 10. Sequence of the CTD of human topoisomerase IIα . Positively 
charged amino acid clusters corresponding to those of bacterial DNA gyrase 
and topoisomerase IV are demarcated by red bars. Points of C-terminal 
truncations in topoisomerase IIα mutant enzymes are indicated.  
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 (hTop2αΔ1321), respectively. Time courses for the relaxation of negatively and 
positively supercoiled plasmids by wild–type topoisomerase IIα, these truncated 
enzymes, and hTop2αΔ1175 are shown in Figure 11. 
 The recognition of DNA geometry by hTop2αΔ1521 during relaxation was similar 
to that of the full-length enzyme. However, removal of even a single cluster of positively 
charged amino acids from the CTD abolished the ability of topoisomerase IIα to discern 
the handedness of its DNA substrate. Comparable rates of relaxation of negatively and 
positively supercoiled plasmids were observed for hTop2αΔ1501, hTop2αΔ1476, and 
hTop2αΔ1321. These findings imply a role for the positively charged amino acid clusters 
of the CTD of topoisomerase IIα in the recognition of DNA geometry during strand 
passage. They also suggest that the removal of even the most C-terminal cluster of 
positively charged residues has the potential to impact the ability of topoisomerase IIα to 
preferentially remove positive superhelical twists.  
 To further investigate the role of the C-terminal cluster of positive amino acids, a 
chimeric enzyme was constructed (hTop2αΔ1501/β) in which residues 1502-1531 of 
human topoisomerase IIα were replaced with the corresponding C-terminal region of 
topoisomerase IIβ (residues 1585-1621). As seen in Figure 12, the chimeric enzyme did 
not maintain the ability to discern the handedness of DNA supercoils during relaxation. 
These data show that the loss of preferential relaxation of positively supercoiled DNA 
with the removal of even one positively charged amino acid cluster is not due to a general 
loss of CTD size.  Instead, this data provides additional evidence that the most C-terminal 
cluster of positive amino acids in topoisomerase IIα is required to preferentially relax 
positively supercoiled DNA substrates. 
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Figure 11. Time courses for relaxation of negatively and positively 
supercoiled substrates by C-terminally truncated topoisomerase IIα  
mutant enzymes. The ability of hTop2αΔ1521, hTop2αΔ1501, 
hTop2αΔ1476, and hTop2αΔ1321 (lacking zero, one, two and six clusters of 
positive charges, respectively) to relax negatively [(-)SC, open circles] and 
positively supercoiled substrates  [(+)SC, closed circles] is shown. Results 
with full-length human topoisomerase IIα and hTop2αΔ1175 also are 
included. To aid comparisons, levels of DNA relaxation for negatively 
supercoiled substrates were normalized to 1.0 at 30 min.  
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Figure 12. Time course for relaxation of negatively and positively 
supercoiled substrates by hTop2αΔ1501/β . hTop2αΔ1501/β is a chimeric 
enzyme in which residues 1502-1531 of human topoisomerase IIα were 
replaced with the corresponding C-terminal region of topoisomerase IIβ 
(residues 1585-1621)]. Ability of the chimeric enzyme to relax negatively  
[(-)SC, open circles] and positively supercoiled substrates  [(+)SC, closed 
circles] is shown.  Error bars represent the standard deviation of three 
independent assays. 
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 It is notable that the overall rate of relaxation of positively supercoiled DNA 
dropped (~5– to 6–fold) as the length of the mutant enzymes decreased. This suggests 
that the presence of the CTD enhances the DNA relaxation activity of topoisomerase IIα 
with positively supercoiled substrates. In some cases (hTop2αΔ1501, hTop2αΔ1476, and 
hTop2αΔ1321), however, mutant enzymes also displayed a modest (~2–fold) increase in 
the rate of relaxation of negatively supercoiled plasmids or the decatenation of kDNA 
(data not shown). Whether this apparent increase in activity reflects a negative regulatory 
function of the CTD in the relaxation of negatively supercoiled substrates or a slight 
variation in the level of active enzyme in the topoisomerase IIα preparations is not 
known at the present time.  
 
The Ability of Human Topoisomerase I to Distinguish the Handedness of DNA Supercoils 
 As discussed above, topoisomerase I is thought to act ahead of replication forks and 
transcription complexes to relax positively supercoiled substrates. While computer 
simulations have examined the relaxation mechanism of human topoisomerase I on 
under- and overwound substrates (26), few studies have examined the catalytic activity of 
the enzyme on its purported physiological substrate. Thus in vitro studies were performed 
to characterize the ability of this critical cellular enzyme to relax and cleave positively 
supercoiled DNA. 
 
Topoisomerase I Preferentially Relaxes Positively Supercoiled Substrates 
 Similar to topoisomerase IIα, topoisomerase I was found to relax positively 
supercoiled DNA more rapidly than negatively supercoiled DNA (Figure 13). This result  
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Figure 13. Time course for relaxation of negatively and positively 
supercoiled substrates by human topoisomerase I. Ability of the enzyme 
to relax negatively [(-)SC, open circles] and positively supercoiled substrates  
[(+)SC, closed circles] is shown.  Supercoil relaxation is quantified by the 
loss of the initial supercoiled substrate. Error bars represent the standard 
deviation of three independent assays. 
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supports the current model of topoisomerase I cellular action and is not unexpected of an 
enzyme that is proposed to act ahead of replication and transcription machinery. In 
collaboration with Birgitta Knudsen’s group in Aarhus Denmark, this preferential 
relaxation of positively supercoiled DNA by human topoisomerase I was examined in 
more detail (146). Consistent with the results shown in Figure 13, human topoisomerase I 
was found to relax positively supercoiled substrates 20-50 times more rapidly than 
negatively supercoiled substrates under processive conditions (i.e., low salt) and 3-10 
times faster under distributive conditions (i.e. high salt). Additionally, this effect could 
not be attributed to preferential binding of the enzyme to positively supercoiled 
substrates, as no significant difference was observed in experiments that measured the 
ability of negatively and positively supercoiled DNA substrates to compete with a 
radiolabeled linear substrate for binding to an active site topoisomerase I mutant. 
 Topoisomerase I carries out supercoil relaxation by a controlled rotation mechanism. 
Recent single molecule studies suggest that the enzyme relaxes supercoiled DNA in a 
stepwise torque-dependent manner, in which relaxation occurs by rotation of the free 5’-
hydroxyl DNA end around the intact DNA strand (25). A molecular dynamics simulation 
study of topoisomerase I by Sari and Andricioaei proposed that the mechanism of 
controlled rotation differs depending on the handedness of the DNA supercoils in the 
substrate, in part because the direction of rotation of the DNA within the enzyme core 
differs for negatively and positively supercoiled substrates (see Chapter I, Figure 4) (26).  
They suggest that relaxation of negatively supercoiled DNA involves stretching of the 
hinge region of the protein with the assistance of residues in the N-terminal domain, 
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while relaxation of positively supercoiled DNA involves a separation of the lips of the 
enzyme (26).  
 Previous studies have shown the importance of the N-terminal domain of 
topoisomerase I in controlling DNA relaxation of negatively supercoiled DNA (173). 
While the relaxation of negatively supercoiled DNA by wild-type human topoisomerase I 
is inhibited by the anti-cancer compound camptothecin, relaxation of similar substrates 
by topoisomerase I enzymes containing N-terminal truncations was unaffected by the 
drug.  
 Interestingly, in the collaborative study, topoisomerase I enzymes that have N-
terminal truncations exhibited 40– to 60– fold inhibition of positively supercoiled DNA 
relaxation in the presence of camptothecin (146).  These results provide strong evidence 
that the mechanism of controlled rotation relaxation of supercoiled DNA by human 
topoisomerase I does in fact differ depending on the handedness of the supercoiled 
substrate and that regions of the N-terminal domain are important in the control of 
removal of negative supercoils by the enzyme.  
 
Topoisomerase I Preferentially Cleaves Positively Supercoiled DNA 
   As discussed above, topoisomerase cleavage complexes formed ahead of DNA 
tracking systems (i.e., on positively supercoiled portions of the genome) are those most 
likely to be converted to permanent strand breaks (11,15,27,28,174-176). Given the 
importance of the topoisomerase I-DNA cleavage reaction to the physiological and 
pharmacological functions of the enzyme, the ability of human topoisomerase I to cleave 
positively supercoiled substrates was examined.  
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Figure 14. Topoisomerase I maintains higher levels of cleavage 
complexes with positively supercoiled DNA. The ability of increasing 
concentrations of human topoisomerase I to cleave positively [(+)SC, closed 
circles] and negatively [(–)SC, open circles] supercoiled pBR322 plasmid 
DNA is shown. Error bars represent the standard deviation of at least three 
independent experiments.  
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 As a first step in characterizing the cleavage activity of human topoisomerase I, 
enzyme-mediated DNA cleavage of overwound and underwound DNA was assessed over 
a broad enzyme concentration range (~3–45 nM). As seen in Figure 14, topoisomerase I 
demonstrated the ability to discern the geometry of DNA over the entire concentration 
range, maintaining a concentration of cleavage complexes that was ~3 times greater with 
substrates that contained positive as compared to negative supercoils. 
  
Conclusions 
Topoisomerase IIα preferentially removes positive superhelical twists, and the 
ability of the enzyme to distinguish DNA supercoil geometry during relaxation is 
embedded in the CTD of the enzyme. Though no structural data is available for the CTD, 
sequence alignment with bacterial type II enzymes reveals 10 clusters of positively 
charged amino acids that are similar to those that fold into DNA-interacting blades in 
gyrase and topoisomerase IV.  Results show that removal of even one of these positively 
charged clusters attenuates the ability of topoisomerase IIα to preferentially relax 
positively supercoiled substrates.     
 Experiments described in this chapter also show that human topoisomerase I relaxes 
positively supercoiled substrates more rapidly than negatively supercoiled substrates.  
However, this enzyme also maintains ~3– to 4– fold higher concentrations of cleavage 
complexes on positively supercoiled DNA. Taken together, these findings strongly 
suggest that human topoisomerase I is an enzyme that is designed to act primarily on 
overwound substrates.  
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   However, because topoisomerase I maintains higher concentrations of cleavage 
complexes on positively supercoiled DNA, this is an inherently dangerous enzyme to 
have ahead of replication forks, as stabilization of topoisomerase I-cleavage complexes 
on this substrate are more likely to result in collisions with DNA tracking systems that 
convert transient cleavage complexes to permanent strand breaks. Therefore, the effects 
of DNA supercoil handedness on the actions of topoisomerase I-targeted anti-cancer 
drugs will be explored in the following chapter.  
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CHAPTER IV 
 
THE GEOMETRY OF DNA SUPERCOILS AFFECTS THE ACTIVITY OF 
TOPOISOMERASE–TARGETED AGENTS 
 
Introduction 
 Beyond their important cellular functions, human topoisomerase I and topoisomerase 
II  are targets for a number of highly effective anticancer agents that act at the enzyme-
DNA interface, stabilizing topoisomerase-DNA cleavage complexes 
(20,27,28,80,108,123,167). The accumulation of these cleavage complexes ahead of 
DNA tracking systems is believed to kill cells by several different mechanisms. First, the 
presence of cleavage complexes or accumulating positive supercoils ahead of the 
replication or transcription machinery impairs these essential cellular functions. Second, 
the presence of blocked replication forks induces replication re-start pathways that 
generate DNA strand breaks. Third, collisions between DNA tracking systems and 
covalent topoisomerase roadblocks convert transient cleavage complexes to permanent 
DNA strand breaks (20,27,28,80,108,123,167,176).  
 As discussed in Chapter III, type II topoisomerases maintain lower levels (~2– to 4–
fold) of cleavage complexes with positively supercoiled as opposed to negatively 
supercoiled DNA (79,145,157). While this feature makes the enzyme safer to function 
ahead of replication and transcription complexes, it may make topoisomerase II less 
sensitive to the actions of anticancer drugs. In contrast, human topoisomerase I maintains 
higher levels of cleavage complexes with positively supercoiled substrates (146,157). 
This property makes the type I enzyme a potentially better target for therapeutic agents. 
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However, it also suggests that topoisomerase I is intrinsically more dangerous to the cell 
than the type II enzyme.  
Because of the fundamental role that topoisomerase I plays in a number of critical 
nuclear processes and in the treatment of human malignancies, it is important to more 
fully characterize the actions of anticancer drugs against topoisomerase I on a positively 
supercoiled substrate. Thus, results in this chapter will show that topoisomerase I 
maintains higher levels of cleavage complexes with positively as opposed to negatively 
supercoiled substrates in the presence of several classes of topoisomerase I poisons. 
Furthermore, this effect correlates with a decreased rate of ligation with overwound 
DNA. Finally, the effects of intercalative compounds on the actions of both 
topoisomerase I and topoisomerase II on under- and overwound DNA will be discussed. 
Results show that intercalating agents that make covalently closed DNA appear to be 
positively supercoiled enhance topoisomerase I-mediated DNA cleavage in vitro and in 
cultured human cells.  
 
Results and Discussion 
 
Effect of DNA Supercoil Geometry on Cleavage Mediated by Human Topoisomerase I in 
the Presence of Camptothecin-based Anticancer Drugs 
 
 Camptothecin-based compounds have been in clinical use for over a decade (27,28).  
Topotecan is approved to treat ovarian, cervical and small cell lung cancers that are 
refractory to other courses of treatment. Irinotecan, a prodrug converted to its active 
metabolite in vivo by carboxylesterase, is used to treat colorectal cancers. Belotecan is 
used to treat ovarian cancer. A third camptothecin derivative, gimatecan, is in clinical 
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trials and shows some activity in treating gliomas (27,28,108). However, the activity of 
these compounds has not been examined in depth on their proposed primary 
physiological substrate. Therefore, as a first step in characterizing the actions of 
topoisomerase I poisons in the context of positively supercoiled DNA, the ability of 
camptothecin and topotecan to poison human topoisomerase I was determined on 
underwound and overwound substrates.   
 As seen in Figure 15, higher levels of cleavage were observed with camptothecin 
and topotecan and positively supercoiled DNA. In both cases, ~3–fold more drug-
induced scission was observed with positively supercoiled (as compared to negatively 
supercoiled) substrates over the range of camptothecin and topotecan concentrations 
examined. Because this level of enhancement is similar to that seen in the absence of 
topoisomerase I poisons, it is proposed that increased drug efficacy on overwound DNA 
is due primarily to an increase in baseline levels of cleavage rather than an altered drug 
interaction in the enzyme-DNA complex.  
 
Mechanistic Basis for Increased Topoisomerase I-mediated DNA Cleavage of Positively 
Supercoiled Substrates 
 
 Although topoisomerase I preferentially relaxes and cleaves overwound molecules, it 
binds positively and negatively supercoiled DNA with similar affinities (146). Therefore, 
the enhanced cleavage of overwound molecules must result from a different aspect of the 
enzyme-DNA interaction. One possibility is that topoisomerase I cleaves a broader 
selection of sites in overwound DNA. Therefore, sites of enzyme-mediated scission were 
mapped in positively and negatively supercoiled substrates. Mapping in the absence of 
drugs is difficult due to the low level of cleavage. Consequently, topotecan was included  
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Figure 15. Effects of DNA supercoil handedness on topoisomerase I-
mediated DNA cleavage in the presence of anticancer drugs. The ability 
of topoisomerase I to cleave positively [(+)SC, closed circles] and 
negatively [(–)SC, open circles] supercoiled pBR322 plasmid DNA in the 
presence of 0–10 µM camptothecin (left panel) or topotecan (right panel) is 
shown. Error bars represent the standard deviation of four independent 
experiments. 
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Figure 16. Effects of DNA supercoil handedness on sites of 
topoisomerase I-mediated DNA cleavage. DNA sites cleaved by 
topoisomerase I were mapped in negatively [(–)SC] and positively [(+)SC] 
supercoiled pBR322 plasmid DNA in the absence (TOP1) or presence (TPT) 
of 5 µM topotecan. Untreated DNA is shown as a control (DNA). Major and 
minor sites of cleavage are denoted by arrows and asterisks, respectively. 
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in experiments to increase the overall level of scission. Four to five major and several 
minor sites of cleavage were observed in the presence of the anticancer drug (Figure 16). 
In general, corresponding sites were observed in both substrates, but levels of scission 
were higher when positively supercoiled plasmid was used. Thus, differences in site 
specificity probably are not the major cause for the enhanced cleavage with overwound 
substrates. 
 A second possibility is that topoisomerase I maintains higher concentrations of 
cleavage complexes with overwound molecules because the enzyme ligates these 
substrates more slowly. In the absence of drugs, rates of enzyme-mediated ligation are 
too quick to monitor at the bench. Therefore, camptothecin or topotecan (both of which 
reduce the rate of ligation) were included in assays. In the presence of either drug, 
topoisomerase I ligated positively supercoiled plasmids more slowly than it did 
negatively supercoiled DNA (Figure 17). Relative rates of ligation (based on calculated 
apparent first order constants) for positively vs. negatively supercoiled DNA were ~2.6– 
and 7.0–fold slower in reactions that contained camptothecin and topotecan, respectively. 
On the basis of this finding, it is proposed that topoisomerase I maintains higher levels of 
cleavage complexes with overwound substrates (at least in part) because it ligates them 
more slowly than it does underwound DNA.  
 
Effects of DNA Supercoil Geometry on Cleavage Mediated by Human Topoisomerase I in 
the Presence of Non-camptothecin Poisons 
 
 Camptothecin-based compounds have several limitations, including severe side 
effects and spontaneous inactivation at physiological pH by opening of the E-ring of the 
compounds (27,28,112).  Because of these limitations and because drugs with common  
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Figure 17. Effects of DNA supercoil handedness on topoisomerase I-
mediated DNA ligation in the presence of anticancer drugs. The ability 
of topoisomerase I to ligate positively [(+)SC, closed circles] and negatively 
[(–)SC, open circles] supercoiled pBR322 plasmid DNA was monitored in 
the presence of 10 µM camptothecin (left panel) or 5 µM topotecan (right 
panel). DNA ligation was initiated by the addition of 300 mM NaCl. Levels 
of cleavage at time zero were set to 100%. Error bars represent the standard 
deviation of three independent experiments.  
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primary cellular targets often display different clinical activities, several classes of novel 
non-camptothecin topoisomerase I poisons currently are being developed (27,28,108) 
(Figure 18). Three classes of compounds thus far have clinical potential. The 
indolocarbazoles are based on naturally occurring alkaloids and have undergone early 
phase clinical trials (27,120). The phenanthridines are expected to enter clinical trials in 
the near future (27).  Finally, several idenoisoquinolines, a class of drugs discovered as 
novel topoisomerase I inhibitors by the Developmental Therapeutics Program at the 
National Cancer Institute, have been selected for clinical development (27,177,178).  
 To examine the activity of non-camptothecin based topoisomerase I poisons on 
positively supercoiled DNA, three compounds were utilized.  The first, rebeccamycin, is 
an indolocarbazole antitumor antibiotic (120). This drug has been shown to poison 
topoisomerase I in vitro and in cells. Moreover, yeast that display reduced sensitivity to 
camptothecin maintain sensitivity to rebeccamycin (179).  As seen in Figure 19, though 
not as potent a poison as camptothecin or topotecan, rebeccamycin induced 3– to 4–fold 
higher concentrations of cleavage complexes with overwound substrates.  
 Two idenoisoquinolines, NSC706744 and NSC725776, also were examined.  This 
class of topoisomerase I poisons display several characteristics that make them favorable 
candidates for clinical development.  First, they do not display the chemical instability 
seen with camptothecin-based compounds. Second, they display different site selectivity 
than camptothecins.  Finally, they are not substrates of ABC membrane transporters, 
which suggests that the idenoisoquinolines may not display drug resistance in the same 
instances as camptothecins (28). As seen in Figure 20, both idenoisoquinoline 
compounds displayed activity similar to that of topotecan, with NSC706744 being a more  
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Figure 18. Non-camptothecin–based topoisomerase I targeted agents. 
Representatives of three classes of drug compounds that target 
topoisomerase I and have clinical potential are shown.   
Idenoisoquinoline Indolocarbazole 
Rebeccamycin: 
Phenanthridine 
Topovale: 
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Figure 19. Effects of DNA supercoil handedness on topoisomerase I-
mediated DNA cleavage in the presence of the indolocarbazole 
rebeccamycin. The ability of topoisomerase I to cleave positively [(+)SC, 
closed circles] and negatively [(–)SC, open circles] supercoiled pBR322 
plasmid DNA in the presence of 0–100 µM rebeccamycin is shown. Error 
bars represent the standard deviation of three independent experiments. 
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Figure 20. Effects of DNA supercoil handedness on topoisomerase I-
mediated DNA cleavage in the presence of idenoisoquinolines. The 
ability of topoisomerase I to cleave positively [(+)SC, closed circles] and 
negatively [(–)SC, open circles] supercoiled pBR322 plasmid DNA in the 
presence of 0–10 µM NSC706744 (left panel) and NSC725776 (right panel) 
is shown. Error bars represent the standard deviation of at least three 
independent experiments. 
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potent poison of topoisomerase I than NSC725776.  The drugs also maintained 3– to 4–
fold higher levels of topoisomerase I-cleavage complexes on positively supercoiled 
substrates. As with the camptothecins, it is proposed that increased drug efficacy on 
overwound DNA in the presence of rebeccamycin and the idenoisoquinoline compounds 
is due primarily to an increase in baseline levels of cleavage rather than an altered drug 
interaction in the enzyme-DNA complex. 
 
Effects of DNA Intercalators on Underwound and Overwound DNA 
 In contrast to topoisomerase I, topoisomerase II maintains lower concentrations of 
cleavage complexes with positively supercoiled substrates both in the absence of drugs 
and in the presence of classic non-intercalative poisons such as etoposide. However, this 
attribute does not hold in the presence of compounds that intercalate into DNA (157). 
The binding of intercalators to DNA locally opens (i.e., underwinds) the double helix 
(157,180,181). In a covalently closed plasmid, this local underwinding is balanced by a 
compensatory global overwinding of the unconstrained (i.e., unbound) DNA. Thus, even 
though the overall topological state of the plasmid has not changed, the presence of 
intercalative agents make the DNA available to the enzyme appear to be positively 
supercoiled (Figure 21). 
 Ethidium bromide, a strong DNA intercalator that does not enhance topoisomerase 
II-mediated cleavage, inhibits the ability of the type II enzyme to cleave negatively 
supercoiled DNA ~6–fold and positively supercoiled DNA ~2–fold. Interestingly, 
concentrations of cleavage complexes on negatively and positively supercoiled substrates 
are virtually identical at concentrations of ethidium bromide at which maximum DNA 
 71 
intercalation has occurred (157). However, intercalative topoisomerase II poisons have a 
markedly different effect on enzyme-mediated DNA cleavage. In the presence of 
intercalative poisons topoisomerase II-mediated cleavage of negatively supercoiled 
substrates increases at low drug concentrations then drops as full drug intercalation is 
reached. In contrast, cleavage of positively supercoiled substrates increases with drug 
concentration and plateaus at concentrations of full drug intercalation (157).  
 The above results are thought to result from two effects on DNA. First, as drug 
intercalates into the DNA, the overall topological state of the substrate appears to be 
more positively supercoiled. The drop in cleavage levels seen with intercalative 
compounds on negatively supercoiled substrates can be explained by the lower baseline 
levels of DNA scission that topoisomerase II maintains on overwound substrates 
(79,157). Additionally, drug accumulation in the double helix could be inhibiting enzyme 
binding and catalysis. This does not, however, explain the higher levels of scission 
generated in the presences of intercalative poisons on overwound substrates. Positively 
supercoiled plasmids are under positive torsional stress even in the absence of 
intercalator.  Thus, it is likely that overwound molecules cannot bind as many 
intercalative compounds as underwound DNA. Therefore, topoisomerase II activity on 
positively supercoiled substrates is less likely to be inhibited by the accumulation of 
intercalative compounds in the genetic material. 
 To test the theory that overwound molecules bind lower levels of intercalative 
compounds compared to underwound molecules, the effects of ethidium bromide binding 
into positively and negatively supercoiled DNA were determined. Briefly, increasing 
concentrations of under- and overwound plasmids were subjected to electrophoresis on 
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Figure 21. Intercalative compounds effect the appearance of covalently 
closed DNA. The binding of intercalators to DNA locally opens (i.e., 
underwinds) the double helix. In a covalently closed plasmid, this local 
underwinding is balanced by a compensatory global overwinding of the 
unconstrained (i.e., unbound) DNA.  
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Figure 22. Overwound plasmids bind less ethidium bromide than 
underwound. The ability of 10-200 ng of negatively [(–)SC, open circles] 
or positively [(+)SC, closed circles]  supercoiled plasmids to bind 0.5 µM or 
1 µM ethidium bromide was determined. Concentration of plasmid DNA 
was confirmed by spectrophotometric analysis. Top, representative agarose 
gels. Bottom, quantification of three independent assays. To aid 
comparisons, levels of fluorescence were normalized to that seen with 200 
ng (–)SC DNA. 
 
ng 
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agarose gels containing increasing concentrations of ethidium bromide.  As can be seen 
in Figure 22, negatively supercoiled plasmids exhibited higher amounts of fluorescence 
than did positively supercoiled. Indeed, overwound molecules displayed 2– to 3–fold 
lower relative fluorescence than did underwound substrates. There is no evidence that the 
handedness of DNA supercoils affects the intrinsic fluorescence properties of ethidium 
bromide. Therefore, this set of experiments serves as proof of principle that differences in 
levels of fluorescence between the two substrates can best be interpreted as a decreased 
binding of ethidium bromide in positively supercoiled plasmids. A decreased binding of 
intercalative compounds to positively supercoiled DNA could expand the effective 
concentration range over which intercalative topoisomerase II poisons enhance cleavage 
complex formation. 
  
DNA Intercalators as Topological Poisons of Topoisomerase I 
 Because intercalators make DNA available to topoisomerases appear to be positively 
supercoiled, and topoisomerase I prefers a positively supercoiled substrate, it was 
hypothesized that an intercalative topoisomerase I poison might have enhanced activity 
compared to a non-intercalative poison. However, to date there are no known compounds 
that both intercalate into DNA and poison human topoisomerase I in a practical 
concentration range. Therefore, the effects of several general DNA intercalators on 
topoisomerase I cleavage were determined. Four different intercalators, ethidium 
bromide, 9-aminoacridine, TAS-103, and amsacrine, were employed. Significant 
intercalation was observed over the concentration ranges employed (see Figure 23, 
insets).  
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Figure 23. Effects of DNA intercalators on topoisomerase I-mediated 
cleavage of plasmid DNA. Cleavage of positively [(+)SC, closed circles] 
and negatively [(–)SC, open circles] supercoiled pBR322 plasmid DNA was 
monitored in the presence of ethidium bromide (EtBr), TAS-103, 9-
aminoacridine (9-AA), or amsacrine (m-AMSA). Data were plotted as 
relative (i.e., fold) DNA cleavage enhancement for simplicity. Fold DNA 
cleavage enhancement was calculated by normalizing levels of scission in 
the absence of intercalator to a relative value of 1.0. Error bars represent the 
standard deviation of at least three independent experiments. Insets show 
representative gels of DNA intercalation assays using relaxed plasmids in 
the absence of enzyme (DNA) or in the presence of the indicated 
concentration (µM) of compound (see Experimental Procedures for the 
interpretation of intercalation assays). The positions of supercoiled (FI) and 
nicked circular (FII) molecules are indicated.  
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 As seen in Figure 23, all of the intercalators examined enhanced topoisomerase I-
mediated DNA cleavage when added to negatively supercoiled plasmids. Ethidium 
bromide was the most potent and efficacious of the compounds tested. Approximately 
10–fold enhancement of DNA cleavage was observed at 20 µM ethidium bromide. The 
other three compounds enhanced cleavage ~3– to 6–fold. 
 Two possible conclusions can be drawn from the above results. The intercalators 
may be “topological poisons” of topoisomerase I, enhancing DNA scission by making the 
negatively supercoiled substrate appear to be positively supercoiled. Alternatively, they 
may be previously undescribed “interfacial” topoisomerase I poisons (i.e., poisons such 
as camptothecin that function at the enzyme-DNA interface) (27). Three experiments 
were carried out to distinguish between these possibilities. In the first, the effects of 
intercalators on topoisomerase I-mediated DNA cleavage were determined using 
positively supercoiled substrates. Since these plasmids are already overwound, the 
addition of intercalative compounds should have very little effect on the apparent 
topology of the DNA. In all cases, virtually no enhancement of cleavage was observed 
when intercalators were present in assays that examined overwound substrates (Figure 
23).  
 In the second experiment, levels and sites of topoisomerase I-mediated cleavage in 
the presence of ethidium bromide, 9-aminoacridine, TAS-103, or amsacrine were 
monitored using radioactively end-labeled linear DNA (Figure 24). Since linear DNA is a 
topologically open system, the opening of the double helix by intercalators does not result 
in the accumulation of positive superhelical twists. Intercalator concentrations used in 
this assay corresponded to those that generated maximal cleavage with negatively 
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supercoiled substrates (see Figure 23). No enhancement of cleavage was seen with any of 
the compounds. This is in marked contrast to camptothecin or topotecan, both of which 
greatly increased levels of scission.  
 In the third experiment, the effects of ethidium bromide on topoisomerase I-
mediated DNA cleavage were assessed in the presence of camptothecin or topotecan 
(Figure 25). Once again, the intercalator increased scission only when negatively 
supercoiled plasmid was used. These results suggest that ethidium bromide affects 
topoisomerase I cleavage by a mechanism that is distinct from that of interfacial poisons 
such as camptothecin and topotecan. 
 Taken together, these findings provide strong evidence that the intercalative 
compounds examined have no intrinsic activity against topoisomerase I and are not 
classical interfacial poisons. Since intercalators only affected enzyme-mediated DNA 
cleavage when underwound covalently closed substrates were employed, it is concluded 
that these compounds are topological poisons of topoisomerase I and enhance enzyme-
mediated scission by altering the apparent superhelical state of the double helix. 
 
Effects of Intercalators on Topoisomerase I-mediated DNA Cleavage in Cultured Human 
Cells  
 
 Since the genetic material in human cells is globally underwound, DNA intercalators 
might influence the ability of topoisomerase I to cleave the double helix in vivo. To 
assess this possibility, the effects of ethidium bromide on topoisomerase I-mediated DNA 
scission were determined in human CEM cells (Figure 26). Levels of topoisomerase I-
DNA cleavage complexes rose ~2.5–fold when cells were treated with 10 µM ethidium 
bromide. Similar to the in vitro results seen in Figure 27, the intercalator also enhanced 
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Figure 24. Effects of anticancer drugs and DNA intercalators on 
topoisomerase I-mediated cleavage of linear DNA. The ability of 
anticancer drugs [5 µM camptothecin (Cpt) or 10 µM topotecan (Tpt)] and 
DNA intercalating agents [20 µM ethidium bromide (EtBr), 20 µM TAS-
103 (TAS), 100 µM 9-aminoacridine (9-AA), or 200 µM amsacrine 
(AMSA)] to enhance cleavage of a 3’-end labeled DNA substrate was 
determined. The autoradiograph is representative of three independent 
experiments.  
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Figure 25. Effects of DNA intercalators on topoisomerase I-mediated 
cleavage of plasmid DNA in the presence of anticancer drugs. Cleavage 
of positively [(+)SC, closed circles] and negatively [(–)SC, open circles] 
supercoiled pBR322 plasmid DNA was monitored in the presence of  0–20 
µM ethidium bromide and either 2.5 µM camptothecin (left panel) or 5 µM 
topotecan (right panel). Error bars represent the standard deviation of at least 
three independent experiments.  
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Figure 26. Effects of ethidium bromide on topoisomerase I-mediated 
DNA cleavage in cultured human CEM cells. Cells were treated for 1 h 
with no drug (ND), 10 µM ethidium bromide (EtBr), 5 µM topotecan (Tpt) 
or both ethidium bromide and topotecan (Tpt+EtBr). Topoisomerase I-DNA 
complexes were monitored using the ICE bioassay (see inset for a 
representative blot). Levels of topoisomerase I-mediated DNA cleavage in 
the absence of drug were set to a relative value of 1. Error bars represent the 
standard deviation of at least three independent experiments. 
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scission in cells that were treated with 5 µM topotecan. These results indicate that 
ethidium bromide can poison topoisomerase I in human cells.  
 
Conclusions 
 Results in this chapter show that topoisomerase I maintains higher levels of cleavage 
complexes (~3– to 4–fold) with overwound substrates in the presence of camptothecins 
and other topoisomerase I poisons. The handedness of DNA supercoils does not alter the 
cleavage sites utilized in the presence of camptothecin-based compounds. Rather, the 
enhanced cleavage of overwound DNA correlates with decreased rates of enzyme-
mediated DNA ligation on this substrate. Because topoisomerase I maintains higher 
baseline levels of cleavage with positively supercoiled DNA (see Chapter III), it is 
proposed that increased drug efficacy on overwound DNA seen in the presence of 
nonintercalative topoisomerase I poisons examined is due primarily to an increase in 
baseline levels of cleavage rather than an altered drug interaction in the enzyme-DNA 
complex. 
 DNA intercalators that have little or no intrinsic effect on topoisomerase I function 
enhanced the ability of the enzyme to cleave covalently closed negatively supercoiled 
substrates. Therefore, it is suggested that these compounds act by altering the perceived 
topological state of the double helix, making underwound DNA appear to be overwound. 
Due to the novel mechanism of action of intercalators on the type I enzyme, it is 
proposed that these compounds be referred to as topological poisons of topoisomerase I. 
It is notable that two of the intercalators examined are known topoisomerase II poisons 
(129,156).  Therefore, while the primary cellular affects of these drugs likely results from 
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their poisoning of topoisomerase II, indirect poisoning of topoisomerase I due to changes 
in the topological state of DNA might also contribute to drug efficacy. 
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CHAPTER V 
 
INTERACTIONS BETWEEN THE ETOPOSIDE DERIVATIVE F14512 AND 
HUMAN TYPE II TOPOISOMERASES: IMPLICATIONS FOR THE C4 SPERMINE 
MOIETY IN PROMOTING ENZYME-MEDIATED DNA CLEAVAGE 
 
 
Introduction 
 
Results presented in the previous chapters indicate that drugs that change the 
topological state of DNA can profoundly effect the responses of type I and type II 
topoisomerases. This chapter explores the effects that altering a drug to increase its 
ability to interact with DNA has on the ability of the compound to poison type II 
topoisomerases.  
As mentioned in Chapter I, etoposide is a widely prescribed anticancer agent that is 
used as front line therapy to treat a variety of human malignancies (122-125). The drug is 
currently in its fourth decade of clinical use and kills cells by stabilizing covalent 
topoisomerase II-cleaved DNA complexes (20,80,97,104,122-125). Although regimens 
that include etoposide generate successful outcomes against a range of cancers, the 
cytotoxic nature of the drug induces significant side effects, including cardiotoxicity, 
myelosuppression, and gastrointestinal toxicity (122,123,182,183). Furthermore, ~2-3% 
of patients that are treated with etoposide go on to develop specific secondary leukemias 
that involve the mixed lineage leukemia (MLL) gene at chromosomal band 11q23 
(107,125,138,139). Since the toxic side effects of etoposide are predominantly 
mechanism-based (i.e., result from the actions of the drug against topoisomerase II), they 
are difficult to eliminate. Etoposide and other anticancer drugs affect both isoforms of 
human topoisomerase II, topoisomerase IIα and topoisomerase IIβ (20,80,97,104,157). 
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Evidence suggests that topoisomerase IIβ may play a more important role than 
topoisomerase IIα in mediating off-target toxicities and generating leukemic 
chromosomal translocations (142-144). 
 One way to decrease the off-target toxicity of etoposide and related drugs is to 
increase their specificity for malignant tissues. To this point, the polyamine transport 
system is more active in proliferating cells than resting cells, and the uptake of 
polyamines by some cancer cells is even greater (184-187). Therefore, in an effort to 
enhance the uptake of etoposide by cancer cells, F14512 was developed (Figure 27) 
(148,149). This derivative replaces the carbohydrate moiety at the C4 position of 
etoposide, which does not interact with topoisomerase II in the binary enzyme-drug 
complex (159,160), with the polyamine spermine. The spermine moiety is conjugated to 
the etoposide core through a glycyl spacer and was selected for optimal activity among a 
large series of conjugates (148,149). 
 F14512 is taken up by mammalian cells through the polyamine transport system and, 
compared to etoposide, displays increased potency against most cancer cell lines (148). 
Furthermore, F14512 is more active than the parent compound against a mouse MX-1 
human breast tumor xenograft model and displays a higher therapeutic index and lower 
systemic toxicity (148). The drug also displays high activity against a variety of other 
xenograph models, including solid tumors (188) and leukemia (189), and currently is in 
phase I clinical trials for the treatment of acute myeloid leukemia. 
 Although the spermine moiety originally was attached to F14512 in order to change 
the cellular uptake properties of etoposide, the inclusion of the polyamine had two 
additional effects (148). First, it altered the DNA binding properties of the compound. 
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Figure 27. Structure of etoposide and derivatives. The spermine moiety at 
the C4 position of F14512 is indicated by the box. Asterisks mark protons 
that interact with topoisomerase II in the binary enzyme-drug complex as 
determined by STD [1H]-NMR spectroscopy (26, 27) (see Figure 28 and 
Table 2).  
Etoposide TOP-53 DEPT 
F14512 
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While etoposide displays little interaction with DNA (in the absence of topoisomerase II) 
(190,191), F14512 is a DNA binder, most likely interacting with the double helix through 
the minor groove (148). Second, as determined by preliminary in vitro studies, F14512 
appears to be a more efficacious topoisomerase II poison than etoposide (148). 
 Given the high activity of F14512 in preclinical cancer models, it is important to 
understand how the drug interacts with potential cellular targets. Therefore, the effects of 
the C4 spermine moiety on drug function against human type II topoisomerases were 
analyzed. Results indicate that the C4 polyamine increases the potency and efficacy of 
the drug against both isoforms of human topoisomerase II, but does not change the 
fundamental mechanism of etoposide action (i.e., inhibition of DNA ligation). Rather, the 
linkage between the spermine and the drug core appears to enhance the stability of 
etoposide in the ternary enzyme-drug-DNA complex. 
 
Results and Discussion 
 
Interactions between F14512 and Human Topoisomerase IIα 
 Previous studies indicate that interactions between topoisomerase II and etoposide 
are critical for drug activity and mediate the entry of etoposide into the ternary enzyme-
drug-DNA complex (159,160,192,193). Furthermore, drug contacts in the binary 
topoisomerase II-drug complex, including the C15 geminal protons of the A–ring, the C5 
and C8 protons of the B–ring, and the C2’ and C6’ protons and the 3’– and 5’–methoxyl 
protons of the pendant E–ring (as defined by STD [1H]-NMR spectroscopy, Table 2) 
have predictive value for the actions of etoposide within the ternary drug-enzyme-DNA 
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complex (159,160). Indeed, alterations of A-ring and E-ring substituents dramatically 
decrease the efficacy of etoposide against topoisomerase II. In contrast, removal of the C-
4 glycosidic group (which generates DEPT, Figure 27) has relatively little effect on the 
ability of the drug to poison topoisomerase II (160). 
 F14512 shares an identical core (rings A–E) with etoposide but contains a spermine 
group in place of the glycosidic moiety at the C4 position (Figure 27). Therefore, as a 
first step in characterizing the activity of the compound against human type II 
topoisomerases, STD [1H]-NMR spectroscopy was employed to define the substituents 
on F14512 that contact topoisomerase IIα in the binary enzyme-drug complex. With the 
exception of one additional contact with the enzyme (the C4 proton of the C-ring) the 
substituents on the drug core that contacted topoisomerase IIα in the binary complex 
were identical to those previously described for etoposide (Table 2 and Figure 28) 
(159,160). It is notable that no significant nuclear Overhauser enhancement (NOE) 
signals were observed for any of the protons of the spermine moiety of F14512. This 
result suggests that there is limited interaction, if any, between this portion of F14512 and 
the enzyme.  
 Although the C4 substituents of etoposide and F14512 do not interact with 
topoisomerase IIα, it is possible to substitute this position with a protein-binding group. 
To this point, TOP-53 is a derivative of etoposide that contains a C4 aminoalkyl side 
chain (Figure 27) (194). In contrast to results with etoposide or F14512, every proton 
associated with this side chain of TOP-53 contacts topoisomerase IIα in the binary 
complex (159). Furthermore, the presence of the aminoalkyl group increases the binding  
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Figure 28. Interaction of F14512 with human topoisomerase IIα  as 
determined by STD [1H]-NMR spectroscopy. Difference (top) and 
reference (off-resonance, bottom) spectra are shown. Spectra are 
representative of at least two independent experiments.  
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affinity of TOP-53 for topoisomerase II and significantly enhances the potency and 
efficacy of the drug against the type II enzyme (159,195).  
 In contrast to the C4 aminoalkyl side chain of TOP-53, the spermine moiety of 
F14512 interacts with DNA and converts the drug to a DNA binder (148). Taken 
together, these results suggest that the C4 substituents of compounds in the etoposide 
family have the potential to influence drug activity by two different mechanisms: 
enhanced binding to the enzyme or enhanced binding to DNA. Consequently, the 
influence of the C4 spermine on F14512 activity was investigated more fully. 
 
F14512 Poisons Human Type II Topoisomerases 
 Preliminary results using human topoisomerase IIα suggest that F14512 is a more 
efficacious poison than etoposide (148). Therefore, to examine the activity of F14512 in 
greater detail, the effects of the drug on DNA cleavage mediated by human type II 
topoisomerases were compared to those of etoposide and TOP-53. F14512 was several–
fold more potent and more efficacious than either drug against both topoisomerase IIα 
(Figure 29) and topoisomerase IIβ (Figure 30). In all cases, F14512 generated the highest 
levels of double-stranded, single-stranded, and total topoisomerase II-mediated DNA 
strand breaks (Figure 31). These results demonstrate that the inclusion of the DNA-
binding C4 spermine in F14512 has a marked effect on drug activity. Furthermore, this 
effect is even greater than that generated by the enzyme-binding aminoalkyl group in 
TOP-53. 
 It is notable that F14512 is more active against topoisomerase IIα than 
topoisomerase IIβ. Comparable or higher levels of DNA scission were observed with the  
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Figure 29. F14512 is a potent topoisomerase IIα  poison. The effects of 
etoposide (closed circles), TOP-53 (closed squares), and F14512 (open 
circles) on the cleavage of negatively supercoiled pBR322 plasmid DNA by 
human topoisomerase IIα were determined.  The percentage of double-
stranded (left panel) and single-stranded (right panel) cleavage is shown. 
Error bars represent the standard deviation of 3 independent experiments. 
The inset in the right panel shows an agarose gel of topoisomerase IIα- 
mediated cleavage of negatively supercoiled pBR322 plasmid DNA in the 
absence of drug (α) or in the presence of 15 µM etoposide (E), TOP-53 (T), 
or F14512 (F). A DNA standard (D) also is shown. The positions of 
supercoiled (form I, FI), nicked circular (form II, FII), and linear (form III, 
FIII) molecules are indicated.  
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Figure 30. F14512 is a potent topoisomerase IIβ  poison. The effects of 
etoposide (closed circles), TOP-53 (closed squares), and F14512 (open 
circles) on the cleavage of negatively supercoiled pBR322 plasmid DNA by 
human topoisomerase IIβ were determined.  The percentage of double-
stranded (left panel) and single-stranded (right panel) cleavage is shown. 
Error bars represent the standard deviation of 3 independent experiments.  
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α isoform, despite the fact that the enzyme concentration employed was only one half 
that used in topoisomerase IIβ assays. Furthermore, at concentrations of F14512 that 
exceeded 15 µM, multiple cleavage events per plasmid were observed with 
topoisomerase IIα, such that it became impossible to accurately quantify levels of 
double-stranded DNA breaks (Figure 29). It has been suggested the α isoform of human 
topoisomerase II may be a more important therapeutic target for topoisomerase II-
directed anticancer agents than topoisomerase IIβ, while the latter isoform contributes 
more to the off-target toxicities of these drugs (142-144). Consequently, the higher 
activity that F14512 displays against topoisomerase IIα may provide therapeutic 
advantages. 
 Eukaryotic type II topoisomerases are homodimeric proteins (50,196,197). Each 
protomer active site of the enzyme cuts one strand of the DNA to generate a double-
stranded break (51). The two enzyme protomers are not fully coordinated and, as a result, 
also create single-stranded breaks (198-200). The double-stranded:single-stranded 
cleavage ratio differs between drug classes, with etoposide yielding a relatively low ratio 
(~0.5:1 at 10 µM drug) with topoisomerase IIα (Figure 31, inset) (198). Of the three 
drugs, F14512 induced the highest ratio of double-stranded:single-stranded breaks (~1:1 
at 10 µM drug with topoisomerase IIα) (Figure 31, inset). 
 Type II topoisomerases require ATP binding and hydrolysis for overall catalytic 
activity (56-58). Numerous studies have demonstrated that etoposide displays maximal 
activity only in the presence of the high-energy cofactor (201), although the mechanistic 
basis for this property is not understood. As seen in Figure 32, levels of topoisomerase 
IIα-mediated DNA cleavage induced by etoposide and TOP-53 drop ~3– and ~2–fold,  
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Figure 31. F14512 is a potent topoisomerase II poison. The effects of 
etoposide (closed circles), TOP-53 (closed squares), and F14512 (open 
circles) on total DNA cleavage mediated by human type II topoisomerases 
were determined. The percentage of total DNA cleavage by topoisomerase 
IIα (left panel) and IIβ (right panel) is shown. Error bars represent the 
standard deviation of 3 independent experiments. The inset in the left panel 
shows the ratio of double-stranded:single-stranded (DS/SS) breaks generated 
by topoisomerase IIα in the presence of 10 µM etoposide ) (E), TOP-53 (T), 
or F14512 (F).  
 
Alpha Beta 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Effects of ATP on drug-stimulated DNA cleavage mediated 
by human topoisomerase IIα . Assays were carried out in the absence 
(closed bars) or presence (open bars) of 0.5 mM ATP. Reactions contained 
no drug (ND) or 10 µM etoposide, TOP-53, or F14512.  Error bars represent 
the standard deviation of 3 independent experiments.  
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respectively, in the absence of ATP. In contrast, F14512 was far better at maintaining 
activity in the absence of ATP, with cleavage levels declining only 15% in assays that 
lacked the cofactor.  
 Because the C4 spermine moiety of F14512 interacts with DNA, it is possible that it 
alters the cleavage site specificity of topoisomerase IIα and topoisomerase IIβ. In order 
to assess this issue, the DNA sites that are cleaved by the human enzymes in the presence 
of etoposide, TOP-53, and F14512 were determined (Figure 33). A similar (but not 
identical) array of sites was cleaved with all three drugs. This finding suggests that the 
addition of the spermine moiety to the etoposide core does not promote site-specific 
DNA interactions and is consistent with the general DNA properties of the polyamine.  
 Etoposide increases levels of covalent topoisomerase II-DNA cleavage complexes 
by inhibiting the ability of the enzyme to ligate DNA breaks (137,202). Therefore, a 
ligation assay was employed to determine whether the inclusion of the spermine moiety 
alters the mechanistic basis for drug action. As seen in Figure 34, etoposide, TOP-53, and 
F14512 are all potent inhibitors of DNA ligation mediated by human topoisomerase IIα. 
Given the strong inhibition, it is not possible to determine whether the higher levels of 
DNA cleavage generated by F14512 reflect an enhanced inhibition of the ligation 
reaction. 
 
F14512–DNA Interactions are Non-intercalative 
 It has long been known that etoposide binds weakly if at all to DNA in the absence 
of topoisomerase II (190,191). In contrast, a previous study that assessed changes in 
DNA melting temperatures, as well as the ultraviolet and circular dichroism spectra of 
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Figure 33. Effects of etoposide derivatives on sites of DNA cleavage 
mediated by human topoisomerase IIα  (left) and topoisomerase IIβ  
(right). An autoradiogram of a polyacrylamide gel is shown. DNA cleavage 
reactions were carried out in the absence of drug (TII), or in the presence of 
the indicated concentrations of F14512, TOP-53, or etoposide. A DNA 
standard (DNA) also is shown. Results are representative of 3 independent 
experiments.  
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Figure 34. Effects of etoposide derivatives on DNA ligation mediated by 
human topoisomerase IIα . Reactions were carried out in the absence of 
drug (open squares) or in the presence of 50 µM etoposide (closed circles), 
50 µM TOP-53 (closed squares), or 10 µM F14512 (open circles). Ligation 
is expressed as the percent loss of linear DNA, which was set to 100% at 
time zero.  Error bars represent the standard deviation of 3 independent 
experiments.  
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DNA, concluded that F14512 is a DNA binding drug (148). While changes in circular 
dichroism suggest that F14512 binds to the double helix through the minor groove, the 
study did not determine the DNA binding mode of the drug (148).  
 A previous study found that attachment of spermine to anthracene (which is a poor 
DNA intercalator) generated an intercalative drug (203). Therefore, two experiments 
were carried out to determine whether F14512 intercalates into DNA. The first 
experiment utilized a topoisomerase I-DNA relaxation assay to monitor intercalation. As 
seen in Figure 35 (top), F14512 displayed no ability to intercalate over the concentration 
range that promoted topoisomerase II-mediated DNA cleavage (0–100 µM). 
 The second experiment takes advantage of the finding that topoisomerase IIα 
maintains 2– to 3–fold higher levels of DNA cleavage complexes with negatively 
supercoiled DNA as compared to positively supercoiled molecules (79,145). While this 
relationship is maintained over a broad concentration range in the presence of non-
intercalative topoisomerase II poisons, as described in Chapter IV, it does not hold when 
intercalative drugs are utilized (145). In this latter case, cleavage levels of negatively 
supercoiled plasmids relative to positively supercoiled substrates drop as the 
concentration of intercalator increases. Over the concentration range of F14512 
examined, the percent cleavage of negatively supercoiled plasmids remained 2– to 3–fold 
higher than seen with the corresponding positively supercoiled substrate (Figure 35, 
bottom). These findings provide strong evidence that F14512 does not utilize an 
intercalative mode to bind DNA. 
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Figure 35. F14512 is not a DNA intercalator. The ability of F14512 to 
intercalate into negatively supercoiled pBR322 plasmid DNA was 
determined using a topoisomerase I relaxation assay (top). An agarose gel is 
shown. DNA relaxation was carried out in the absence of drugs (TI), or in 
the presence of 0–100 µM F14512, 20 µM ethidium bromide (EB), or 20 
µM etoposide (Etop). A DNA standard (D) also is shown. The gel is 
representative of three independent experiments. The bottom panel shows 
the effects of F14512 on the ability of human topoisomerase IIα to cleave 
negatively (open circles) and positively (closed circles) supercoiled pBR322 
plasmid molecules. Error bars represent the standard deviation of 3 
independent experiments.  
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Enhanced Stability of the Ternary Topoisomerase IIα-F14512-DNA Complex 
 
 F14512 displays similar contacts as etoposide with human topoisomerase IIα in the 
binary enzyme-drug complex (see Table 2 and Figure 28), but has additional interactions 
with the double helix in the binary DNA-drug complex (148). Since F14512 is a more 
potent topoisomerase II poison than etoposide, we wanted to see if these DNA 
interactions contribute to an enhanced stability of the spermine-linked drug in the ternary 
topoisomerase IIα-drug-DNA complex. Two approaches were used to address this issue. 
In the first, the persistence of DNA cleavage complexes established in the presence of 
F14512 or etoposide was determined (162). This was accomplished by establishing DNA 
cleavage-ligation equilibria in the presence of 10 µM F14512 or 100 µM etoposide, 
diluting reaction mixtures 20–fold, and monitoring the decay of cleavage complexes over 
time. As seen in Figure 36, cleavage complexes formed in the presence of F14512 
persisted 5– to 10–fold longer than equivalent complexes induced by etoposide. This 
suggests that F14512 forms a more stable ternary complex than etoposide.   
 In the second approach, the ability of the quinolone ciprofloxacin to compete with 
F14512 or etoposide for binding in the ternary complex was determined. Ciprofloxacin is 
an antibacterial topoisomerase II poison (101,204) that displays little ability to stimulate 
DNA cleavage mediated by the eukaryotic type II enzyme (205). However, the quinolone 
interacts with eukaryotic topoisomerase II and shares a binding site with anticancer drugs 
(205). Thus, it can inhibit the ability of these drugs to enhance DNA scission (205).   
 As seen in Figure 37, ciprofloxacin competed with both F14512 and etoposide, but 
the ciprofloxacin:F14512 ratio required to decrease DNA cleavage was 5– to 10–fold 
higher than seen with etoposide. Taken together, these experiments indicate that ternary 
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Figure 36. Effects of etoposide derivatives on the persistence of ternary 
topoisomerase IIα-drug-DNA cleavage complexes. Assays were carried 
out in the presence of etoposide (100 µM) or F14512 (10 µM) and 
negatively supercoiled pBR322 plasmid DNA. After initial reaction mixtures 
attained DNA cleavage-ligation equilibria, they were diluted 20–fold with 
DNA cleavage buffer. The persistence of cleavage complexes was assessed 
by monitoring the loss of double-stranded DNA breaks (linear product) over 
time.  Cleavage at time zero was set to 100%.  Error bars represent the 
standard error of 2 independent assays.  
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Figure 37. F14512 binds more tightly than etoposide in the ternary 
topoisomerase IIα-drug-DNA complex. A ciprofloxacin competition assay 
was employed. DNA cleavage complexes were established in the presence 
of etoposide (Etop), F14512, or a 1:1 mixture of DEPT + spermine and 0–
1000 µM ciprofloxacin (Cipro). Levels of DNA cleavage generated by 
human topoisomerase IIα in the presence of ciprofloxacin alone were 
subtracted from those seen in the presence of etoposide derivatives + 
ciprofloxacin. Cleavage in the absence of ciprofloxacin was set to 100%, and 
results are presented as a ratio of ciprofloxacin concentration to etoposide 
derivative. Error bars represent the standard deviation of 3 independent 
experiments.  
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enzyme-drug-DNA complexes formed in the presence of F14512 are more stable than 
those formed with etoposide. This enhanced stability provides a probable basis for the 
greater potency and efficacy of F14512 compared to etoposide. 
 
Importance of the Spermine-Drug Linkage to the Enhanced Activity of F14512 Against 
Topoisomerase IIα 
 Experiments in the previous section suggest that the spermine-mediated binding of 
F14512 to DNA is responsible for the enhanced activity of the drug. However, spermine-
DNA interactions also neutralize nucleic acid charge and allow condensation of the 
double helix (206-208). Furthermore, polyamines such as spermine and spermidine can 
alter interactions between type II topoisomerases and DNA and are used routinely as 
DNA condensation agents to convert intramolecular to intermolecular DNA strand 
passage reactions (i.e., DNA relaxation to catenation) (209). 
 Therefore, to determine whether the spermine moiety alters F14512 activity by a 
specific effect on drug interactions in the ternary complex or by a general effect on DNA 
charge/structure, the importance of the spermine-drug linkage to the activity of F14512 
was examined. As a first step, the stability of the ternary enzyme-drug-DNA complex 
was assessed when it was formed in the simultaneous presence of the unlinked etoposide 
core (i.e., DEPT, see Figure 27) and spermine. As assessed by the ciprofloxacin 
competition assay (Figure 37), the stability of a 1:1 DEPT:spermine mixture was similar 
to that of etoposide and was ~10–fold lower than that of F14512. This finding indicates 
that the drug-spermine linkage is critical for the enhanced stability of F14512 in the 
ternary complex.  
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The effects of the drug-spermine linkage on the activity of F14512 also were 
determined. As seen in Figure 38, spermine (up to 100 µM) had little influence on levels 
of  DNA cleavage mediated by human topoisomerase IIα (210). Moreover, DNA 
cleavage enhancement observed in the presence of a 1:1 DEPT:spermine mixture was 
comparable to that of the drug core in the absence of the polyamine. A similar result was 
seen comparing a 1:1 etoposide:spermine mixture to the activity of etoposide alone. 
Taken together, these results provide strong evidence that, in the concentration ranges 
examined, spermine does not enhance topoisomerase II-mediated DNA cleavage by a 
general effect on DNA charge or structure. Furthermore, the drug-spermine linkage is 
critical for the high activity of F14512. 
 
Conclusions 
 F14512 is a novel etoposide derivative that contains a spermine group in place of the 
C4 glycosidic moiety (148). The linkage between the drug core and spermine converts 
etoposide to a DNA binder (148). The presence of the spermine also enhances the 
selectivity of the drug in cancers that over-express an active polyamine transport system 
(148,188,189). Results shown here indicate that F14512 is a more potent and efficacious 
topoisomerase II poison than etoposide, and this enhanced activity correlates with an 
increased stability of the ternary topoisomerase II-drug-DNA complex. The covalent 
linkage between the etoposide core and spermine is critical for the enhanced activity of 
F14512. Additionally, the drug is more potent and efficacious than TOP-53, an etoposide 
derivative that contains a C4 aminoalkyl group that strengthens drug-enzyme binding. 
These findings highlight the utility of a C4 DNA binding group and provide a rational 
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Figure 38. The covalent linkage of the C4 spermine moiety to the 
etoposide core is necessary for the enhanced DNA cleavage seen in the 
presence of F14512. The ability of DEPT or a 1:1 mixture of DEPT + 
spermine (left panel), and etoposide (Etop) or a 1:1 mixture of etoposide + 
spermine (right panel) to enhance topoisomerase IIα-mediated DNA 
cleavage is shown. Control experiments assessing the effects of spermine 
alone on the DNA cleavage activity of topoisomerase IIα are shown in both 
panels. Error bars represent the standard deviation of 3 independent 
experiments. 
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basis for the development of novel and more active etoposide-based topoisomerase II 
poisons. Finally, the dual function of the C4 spermine moiety (i.e., enhanced cellular 
uptake in cancers with active polyamine transport and greater activity against 
topoisomerase II) supports the ongoing clinical development of F14512. 
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CHAPTER IV 
 
CONCLUSIONS 
 
 The three-dimensional properties of DNA dramatically affect how the cell accesses 
and reproduces its genetic information. Some of the most important three-dimensional 
relationships in DNA are topological in nature, including underwinding and overwinding, 
knotting, and tangling (3,4,8-11). These topological problems are resolved by the 
concerted actions of DNA topoisomerases (5,6,13,15,16). In addition to their critical 
cellular functions, topoisomerases are the targets for some of the most widely prescribed 
anticancer drugs currently in clinical use (20,27,28,80,104,125). The work presented in 
this dissertation provides a more complete understanding of the interplay between DNA 
interactions, human topoisomerase activity, and anticancer drugs that act at the enzyme-
DNA interface.  
 
Structural Features of Topoisomerases Required for the Recognition of DNA Topology  
During replication, unwinding of the double helix and synthesis of new 
complementary DNA strands results in the accumulation of underwound DNA behind the 
replication fork and overwound DNA ahead of the fork (4,9,11). A similar redistribution 
of DNA supercoils arises during transcription. Chapter III of this dissertation describes 
the regions of topoisomerase IIα that are necessary for recognition of DNA topology 
ahead of replication forks (i.e. overwound DNA).  This chapter also provides strong 
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evidence that topoisomerase I is an enzyme that is designed to act primarily on 
overwound DNA.  
 
Portions of Topoisomerase II Required for Preferential Relaxation of Positively 
Supercoiled DNA 
Topoisomerase IIα recognizes supercoil handedness during relaxation, and removes 
positive supercoils >10 times faster than negative supercoils (79). Experiments presented 
in Chapter III show that almost the entire CTD of topoisomerase IIα is required for this 
activity. Although no structural data of the CTD of this enzyme is available, this protein 
domain contains clusters of positively charged amino acids that could interact with DNA 
in a manner similar to that seen with prokaryotic type II enzymes.  The CTDs of gyrase 
and topoisomerase IV fold into pinwheel structures wherein the clusters of positively 
charged residues form blades that are capable of binding and bending DNA. Attempts to 
express the CTD of topoisomerase IIα apart from the N-terminal and core of the enzyme 
were unsuccessful, likely do to the predicted unstructured nature of this domain apart 
from the rest of the enzyme (James Berger, personal communication).   
To date, only structures of the N-terminal and core domains of eukaryotic 
topoisomerase II are available.  Once more structural data become available, it will be 
interesting to see if the CTD of topoisomerase IIα resembles that of the prokaryotic 
enzymes. However, to narrow down the region(s) of the topoisomerase IIα CTD that is 
responsible for the preferential relaxation of positively supercoiled DNA, a series of 
nested C-terminally deleted enzymes that removed clusters of positively charged amino 
acids was generated. Removing even one blade of positively charged residues from the 
CTD of topoisomerase IIα attenuated the ability of the enzyme to preferentially relax 
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overwound DNA.  Replacing these last 30 amino acid residues with the corresponding 
region of topoisomerase IIβ did not restore this activity.  
Unlike topoisomerase IIα, topoisomerase IIβ does not distinguish supercoil geometry 
for relaxation. However, replacing the CTD of the β isoform with that of the α isoform 
does confer the ability to distinguish supercoil geometry for relaxation (145).  It would be 
interesting to replace just the final cluster of positively charged residues of topoisomerase 
IIβ with those of the α isoform.  While results presented in this dissertation show that the 
last 30 residues of topoisomerase IIα are necessary for preferential relaxation of 
positively supercoiled DNA, swapping these residues of topoisomerase IIα into the CTD 
of topoisomerase IIβ would provide information on whether this cluster alone was 
sufficient. 
 
Topoisomerase I Preferentially Relaxes and Cleaves Overwound DNA 
 If topoisomerase I acts ahead of replication forks to relieve accumulating positive 
supercoils, then it stands to reason that this enzyme would recognize and preferentially 
act on an overwound DNA substrate. Results presented in Chapter III show that 
topoisomerase I preferentially relaxes and cleaves positively supercoiled substrates. 
 Previous studies have shown that truncation of the N-terminal domain of 
topoisomerase I does not effect the ability of the enzyme to relax supercoiled substrates. 
However, while relaxation of negatively supercoiled DNA by full-length topoisomerase I 
is inhibited by the anti-cancer compound camptothecin, relaxation of similar substrates 
by topoisomerase I enzymes containing N-terminal truncations was unaffected by the 
drug (173). Results generated during the collaborative study of topoisomerase I relaxation 
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mentioned in this dissertation showed that relaxation of positively supercoiled substrates 
by N-terminally truncated topoisomerase I enzymes was inhibited in the presence of 
camptothecin. These results suggest that the N-terminal portion of the enzyme, while not 
strictly necessary for enzymatic function, plays a role in the removal of negative 
supercoils.  Whether N-terminal deletions of topoisomerase I differentially affect the 
ability of the enzyme to cleave negatively or positively supercoiled substrates in the 
presence of anticancer drugs is still unknown. 
 The increased concentration of cleavage complexes generated with positively 
supercoiled substrates appears to correlate with decreased rates of enzyme-mediated 
DNA ligation (see Chapter IV). This seems counterintuitive given the fact that 
topoisomerase I also preferentially relaxes positive supercoils (189). However, since the 
enzyme removes multiple superhelical twists per event, ligation may not be the limiting 
step of the relaxation reaction. Alternatively, if the enzyme is less likely to ligate cleaved 
DNA, it may actually remove superhelical twists more rapidly. 
 
The Geometry of DNA Supercoils Affects the Activity of Topoisomerase-targeted Agents 
 Beyond their important cellular functions, human topoisomerase I and topoisomerase 
II  are targets for a number of highly effective anticancer agents that act at the enzyme-
DNA interface and stabilize topoisomerase-DNA cleavage complexes 
(20,27,28,80,108,123,167). Type II topoisomerases maintain lower levels (~2– to 4–fold) 
of cleavage complexes with positively supercoiled as opposed to negatively supercoiled 
DNA (79,145,157). While this feature makes topoisomerase II safer to function ahead of 
replication and transcription complexes, it may make the enzyme less sensitive to the 
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actions of anticancer drugs. In contrast, as shown in Chapter III, human topoisomerase I 
maintains higher levels of cleavage complexes (~3–to 4–fold) with positively supercoiled 
substrates. This property makes topoisomerase I a potentially better target for therapeutic 
agents and suggests that the enzyme is intrinsically more dangerous to the cell than 
topoisomerase II. Studies in Chapter IV examine how DNA topology alters the actions of 
anticancer drugs that target human topoisomerases.  
 Results show that topoisomerase I maintains higher concentrations of cleavage 
complexes on overwound substrates in the presence of both camptothecin-based and non-
camptothecin based anticancer drugs. Similar cleavage sites were utilized on both 
substrates. Enhanced topoisomerase I-mediated cleavage of positively supercoiled 
substrates in the presence of these poisons is thought to be due to increased baseline 
levels of cleavage on positively supercoiled substrates rather than an altered drug 
interaction in the enzyme-DNA complex.  
 Unexpected results were generated when intercalative compounds were included in 
topoisomerase I reactions. Intercalation of a compound into a covalently closed plasmid 
causes local unwinding of the double helix at the site of intercalation and compensatory 
positive supercoiling at distal sites on the plasmid.  As topoisomerase I prefers to cleave 
positively supercoiled substrates, it was hypothesized that an intercalative topoisomerase 
I poison might have enhanced activity compared to a non-intercalative poison. Because 
there are as yet no known intercalative topoisomerase I poisons, experiments utilized 
intercalative compounds that do not poison topoisomerase I in the classic interfacial 
manner.  
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 No enhancement of topoisomerase I-mediated cleavage enhancement of positively 
supercoiled or linear DNA was seen in the presence of intercalative compounds.  In 
contrast, cleavage enhancement was seen when a negatively supercoiled substrate was 
employed. At least some of the enhanced topoisomerase I-mediated cleavage of 
underwound DNA seen in the presence of intercalative compound can be ascribed to the 
higher baseline levels of cleavage that topoisomerase I maintains on overwound 
substrates.  However, cleavage enhancement of negatively supercoiled substrates in the 
presence of intercalators exceeded total cleavage levels maintained on positively 
supercoiled substrates. Thus, it is proposed that these compounds are topological poisons 
of topoisomerase I and enhance enzyme-mediated scission by altering the apparent 
superhelical state of the double helix.  
 In light of the in vitro results, and because the genetic material in human cells is 
globally underwound, it was hypothesized that DNA intercalators might also influence 
the ability of topoisomerase I to cleave the double helix in vivo. Indeed, results in Chapter 
IV show that enhanced trapping of topoisomerase I cleavage complexes was seen in a 
human cancer cell line that was treated with ethidium bromide. Treatment of cells with 
both ethidium bromide and topotecan lead to a higher enhancement of cellular 
topoisomerase I cleavage complex trapping than either drug alone. These results indicate 
that intercalative compounds may be capable of poisoning topoisomerase I in vivo. Two 
of the intercalative compounds used in the in vitro studies are known topoisomerase II 
poisons (129,156). Therefore, it would be interesting to examine whether or not 
intercalative topoisomerase II poisons also indirectly affect topoisomerase I activity in 
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vivo. The cellular results also suggest that an intercalative topoisomerase I poison might 
trap more topoisomerase I cleavage complexes in vivo than a non-intercalative poison. 
  
The Effects of Enhanced Drug-DNA Interaction on DNA Cleavage Mediated by 
Topoisomerase II 
 Chapter V examines the effects that attaching a DNA interacting group at the C4 
position of the core of the classic topoisomerase II poison etoposide has on the ability of 
the compound to poison type II topoisomerases. F14512 is an etoposide derivative that 
contains a spermine moiety in place of the C4 glycosidic moiety.  F14512 was originally 
developed to increase the cellular uptake of etoposide by targeting the drug to the 
polyamine transport system which is upregulated in some cancer cells (148).  However, 
the addition of the spermine group had an added effect on the compound in that it turned 
the drug into a DNA binder (148). Experiments in Chapter V show that F14512 is a 
stronger poison of both isoforms of topoisomerase II than is etoposide. Furthermore, 
unlike etoposide, F14512 maintains robust activity in the absence of ATP. The enhanced 
activity of F14512 correlates with an increased stability of the ternary topoisomerase II-
drug-DNA complex, and experiments show that the spermine-drug core linkage is critical 
for this attribute. 
 The ability of F14512 to poison topoisomerase II also was compared to that of TOP-
53.  TOP-53 is an etoposide derivative that contains an aminoalkyl group at the C4 
position. As determined by STD [1H]-NMR spectroscopy, every proton in the C4 group 
of TOP-53 displays interactions with topoisomerase IIα in the absence of DNA; however, 
this drug is not known to interact with DNA in the absence of enzyme. Because no 
interactions were seen between topoisomerase II and the protons in the C4 moiety of 
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F14512, these drugs allow a comparison of similar etoposide-based compounds that have 
enhanced interactions with the enzyme (TOP-53) or DNA (F14512). F14512, the drug 
that interacted more strongly with DNA, was a more potent topoisomerase II poison in 
vitro than the drug (TOP-53) with enhanced enzyme interactions.  Whether these results 
are unique to these two drugs or predictive for other compounds that poison 
topoisomerase II remains to be seen.  
 Drug resistance is a common roadblock to the successful treatment of human 
ailments. Several mechanisms contribute to resistance, including drug efflux, target 
protein down-regulation, and development of point mutations in target proteins that 
render the drug ineffective (27,112,116,211-214). One can speculate that increased 
cellular uptake via the polyamine system and tighter DNA interactions could help to 
counterbalance some drug efflux issues.  Additionally, increased interactions with DNA 
and tighter binding in the enzyme-drug-DNA complex could help to overcome some 
instances of resistance due to protein point mutations.  While topoisomerase point 
mutations are not a major cause of resistance in cancer therapy, antibacterial resistance 
due to type II topoisomerase point mutations is prevalent (215-217). Therefore, it would 
be interesting to see if attaching a spermine group to a known quinolone antibacterial 
topoisomerase II poison enhances the ability of the drug to overcome resistance 
mutations.  
 Ultimately, these findings demonstrate the utility of a C4 DNA binding group and 
provide a rational basis for the development of novel and more active etoposide-based 
topoisomerase II poisons. 
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